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Sleep-related breathing disorders are highly prevalent inpatients with established cardiovascular disease. Obstruc-
tive sleep apnea (OSA) affects an estimated 15 million adult
Americans and is present in a large proportion of patients
with hypertension and in those with other cardiovascular
disorders, including coronary artery disease, stroke, and atrial
fibrillation (1–14). In contrast, central sleep apnea (CSA)
occurs mainly in patients with heart failure (15–19). The
purpose of this Scientific Statement is to describe the types
and prevalence of sleep apnea and its relevance to individuals
who either are at risk for or already have established
cardiovascular disease. Special emphasis is given to recog-
nizing the patient with cardiovascular disease who has coex-
isting sleep apnea, to understanding the mechanisms by
which sleep apnea may contribute to the progression of the
cardiovascular condition, and to identifying strategies for
treatment. This document is not intended as a systematic
review but rather seeks to highlight concepts and evidence
important to understanding the interactions between sleep
apnea and cardiovascular disease, with particular attention to
more recent advances in patient-oriented research. Implicit in
this first American Heart Association/American College of
Cardiology Foundation Scientific Statement on Sleep Apnea
and Cardiovascular Disease is the recognition that, although
holding great promise, this general area is in need of a
substantially expanded knowledge base. Specific questions
include whether sleep apnea is important in initiating the
development of cardiac and vascular disease, whether
sleep apnea in patients with established cardiovascular
disease accelerates disease progression, and whether treat-
ment of sleep apnea results in clinical improvement, fewer
cardiovascular events, and reduced mortality.
Experimental approaches directed at addressing these issues
are limited by several considerations. First, the close association
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between obesity and OSA often obscures differentiation be-
tween the effects of obesity, the effects of OSA, and the effects
of synergies between these conditions. Second, multiple comor-
bidities, including cardiovascular disease, metabolic syndrome,
and diabetes, often are present in patients with sleep apnea.
Hence, it becomes unclear whether abnormalities evident in the
sleep apnea patient with cardiovascular disease are secondary to
the sleep apnea, the cardiovascular condition, or both. The third
consideration relates to randomization of sleep apnea patients to
active or no treatment. Although this is a reasonable strategy for
identifying the mechanistic and prognostic consequences of
sleep apnea per se, it is limited by the difficulties inherent in any
placebo-controlled treatment study of sleep apnea and the need
to consider treatment in patients with severe daytime somno-
lence, even in the absence of associated cardiovascular disease.
Definitions, Classifications, Diagnosis,
and Pathophysiology
Obstructive Sleep Apnea
OSA is characterized by repetitive interruption of ventilation
during sleep caused by collapse of the pharyngeal airway. An
obstructive apnea is a 10-second pause in respiration
associated with ongoing ventilatory effort. Obstructive hy-
popneas are decreases in, but not complete cessation of,
ventilation, with an associated fall in oxygen saturation or
arousal. A diagnosis of OSA syndrome is accepted when a
patient has an apnea-hypopnea index (AHI; number of apneas
and hypopneas per hour of sleep) 5 and symptoms of
excessive daytime sleepiness (20) (Figure 1 and Table 1; see
Table 2 [5] for definitions of terms).
Although hypopneas constitute the majority of disordered
breathing events, there is some controversy regarding the
optimal criteria for definition of hypopneas. A recent analysis
of data from 6000 adults participating in the Sleep Heart
Health Study noted that hypopneas accompanied by oxyhe-
moglobin desaturation of 4% were associated with preva-
lent cardiovascular disease independently of confounding
covariates (21). In contrast, no association was observed
between cardiovascular disease and hypopneas associated
with milder desaturation or arousals. The investigators noted
several limitations of their data, including the facts that
causality cannot be inferred from their cross-sectional anal-
ysis and that additional cross-sectional and longitudinal
Figure 1. Partial and complete airway
obstruction resulting in hypopnea and
apnea, respectively. Reprinted from Hahn
PY, Somers VK. Sleep apnea and hyperten-
sion. In: Lip GYH, Hall JE, eds. Comprehen-
sive Hypertension. St. Louis, MO: Mosby;
2007:201–207. Copyright Elsevier 2007.
Used with permission.
Table 1. Obstructive Sleep Apnea
Signs, symptoms, and risk factors
Disruptive snoring
Witnessed apnea or gasping
Obesity and/or enlarged neck size
Hypersomnolence (not common in children or in heart failure)
Other signs and symptoms include male gender, crowded-appearing
pharyngeal airway, increased blood pressure, morning headache, sexual
dysfunction, behavioral changes (especially in children)
Screening and diagnostic tests
Questionnaires
Holter monitoring
Overnight oximetry
Home-based/ambulatory unattended polysomnography
In-hospital attended overnight polysomnography
Treatment options
Positional therapy
Weight loss
Avoidance of alcohol and sedatives
Positive airway pressure
Oral appliances
Surgery
Uvulopalatopharyngoplasty
Tonsillectomy
Tracheostomy
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studies are needed to compare interactions between event
definitions and other sleep-disordered breathing (SDB)–
related consequences.
Pharyngeal collapse in patients with OSA generally occurs
posterior to the tongue, uvula, and soft palate or some
combination of these structures. This portion of the pharyn-
geal airway (from the posterior nasal septum to the epiglottis)
has relatively little bony or rigid support and is therefore
largely dependent on muscle activity to maintain patency.
The primary abnormality in patients with OSA is an anatom-
ically small pharyngeal airway resulting from obesity, bone
and soft tissue structures, or, in children, tonsils and adenoids
(22). During wakefulness, this leads to increased airflow
resistance and greater intrapharyngeal negative pressure dur-
ing inspiration. Mechanoreceptors located primarily in the
larynx respond reflexively to this negative pressure and
increase the activity of a number of pharyngeal dilator
muscles, thereby maintaining airway patency while awake
(22,23). However, during sleep, the reflex pharyngeal muscle
activity that drives this neuromuscular compensation is re-
duced or lost, leading to reduced dilator muscle activity and
ultimately to pharyngeal narrowing and intermittent complete
collapse (24). During the subsequent apnea or hypopnea,
hypoxia and hypercapnia stimulate ventilatory effort and
ultimately arousal from sleep to terminate the apneic event.
Thus, an upper airway that requires reflex-driven muscle
activation to maintain patency during wakefulness may be
vulnerable to collapse during sleep.
The pathophysiology of obstructive apneas is complex and
varies between patients. Although deficient pharyngeal anat-
omy and variable upper airway dilator muscle control awake
and asleep are likely the predominant causes of pharyngeal
collapse in most patients with OSA, other mechanisms also
likely contribute (25–28). Loss of lung volume during sleep
reduces longitudinal traction on the upper airway, rendering it
more collapsible. In addition, ventilatory control system
instability is associated with cycling respiratory output to
ventilatory pump muscles and upper airway dilator muscles.
As a result, at the nadir of such cycling, the pharyngeal
airway may collapse completely or partially, yielding ob-
structive apneas or hypopneas. Accordingly, in the individual
with ventilatory control instability, apneas/hypopneas may be
central or obstructive, depending on the collapsibility of the
upper airway. Finally, mechanisms such as variable surface
tension in the pharyngeal airway, arousal threshold, and
asynchronous timing of activation of upper airway versus
pump muscles may contribute to apnea pathogenesis.
Screening of patients for SDB can be accomplished by
several different methods, although the sensitivity and specific-
ity of these have not been well documented, particularly in
cardiovascular patients, and may be expected to be affected by
pretest probability. Some of these options include the Epworth
Sleepiness Scale (29), the Berlin questionnaire (30), overnight
oximetry, and devices combining limited respiratory assessment,
ECG, and oximetry (31). Specialized analysis of 24-hour ECG
recordings also has been proposed as a possible screening tool
(32). The available options have many shortcomings. The most
often used in clinical practice is overnight oximetry.
In patients with suspected OSA, a definitive diagnosis
often requires spending a night in a sleep laboratory during
which multiple physiological variables are continuously rec-
orded (polysomnography). These variables generally include
sleep staging using the electroencephalogram, electromyo-
gram, electrooculogram, respiration (flow, effort, oxygen
saturation), and snoring. With these signals, disordered
breathing, in addition to its effect on sleep and oxygenation,
can be precisely quantified. The importance of the cardiovas-
cular response to sleep has been recognized in the recently
revised Sleep Scoring Manual from the American Associa-
tion of Sleep Medicine (AASM) (33), which now includes
scoring of a continuous-lead ECG as a recommended com-
ponent of polysomnography (34).
There is controversy as to whether disordered breathing
during sleep can be adequately assessed using fewer signals
recorded in the home. Most of these systems are limited to
monitoring the respiratory channels listed above and do not
include sleep staging or other nonrespiratory signals. After
careful assessment, the American Academy of Sleep Medicine
concluded that certain home diagnostic methodologies probably
do have a role in the diagnosis of obstructive sleep apnea if used
by an experienced clinician (35). Although this remains contro-
versial, the Center for Medicare Services recently decided to pay
Table 2. Definitions of Terms (5)
Term Definition
Apnea Cessation of airflow for 10 s
Hypopnea A reduction in but not complete cessation of
airflow to 50% of normal, usually in
association with a reduction in
oxyhemoglobin saturation
AHI The frequency of apneas and hypopneas per
hour of sleep; a measure of the severity of
sleep apnea
OSA and hypopnea Apnea or hypopnea resulting from complete or
partial collapse, respectively, of the pharynx
during sleep
CSA and hypopnea Apnea or hypopnea resulting from complete or
partial withdrawal of central respiratory drive,
respectively, to the muscles of respiration
during sleep
Oxygen desaturation Reduction in oxyhemoglobin saturation, usually
as a result of an apnea or hypopnea
Sleep apnea syndrome At least 10 to 15 apneas and hypopneas per
hour of sleep associated with symptoms of
sleep apnea, including loud snoring, restless
sleep, nocturnal dyspnea, headaches in the
morning, and excessive daytime sleepiness
Polysomnography Multichannel electrophysiological recording of
electroencephalographic, electroculographic,
electromyographic, ECG, and respiratory activity
to detect disturbance of breathing during sleep
NREM sleep Non–rapid eye movement or quiet sleep
REM sleep Rapid eye movement or active sleep; associated
with skeletal muscle atonia, rapid movements of
the eyes, and dreaming
Arousal Transient awakening from sleep lasting 10 s
Reprinted from Bradley et al (5), with permission from Lippincott Wiliams &
Wilkins. Copyright 2003, American Heart Association.
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for CPAP when the diagnosis of OSA was made with portable
systems in the home. Thus, the use of such methodologies will
likely increase in the future.
Central Sleep Apnea
CSA is characterized by repetitive cessation of ventilation
during sleep resulting from loss of ventilatory drive. A central
apnea is a10-second pause in ventilation with no associated
respiratory effort. Generally, 5 such events per hour are
considered abnormal. CSA syndrome is present when a
patient has 5 central apneas per hour of sleep and the
associated symptoms of disrupted sleep (frequent arousals)
and/or hypersomnolence during the day (20). Because central
apneas also may occur in an individual with obstructive
apneas, care must be exercised in deciding that CSA rather
than OSA is the principal problem. Although there is no
absolute standard in this regard, studies of patients with CSA
require that 50% of all events be central, with 80%
central events often being required.
CSA does not have any single cause (Figure 2). As a result,
a number of syndromes have emerged, each of which may
have somewhat different underlying pathophysiological
mechanisms. Cheyne-Stokes respiration (CSR) generally oc-
curs in patients with heart failure, although it has been
described in association with neurological disorders, includ-
ing neurovascular disorders and dementia. It is characterized
by a crescendo-decrescendo pattern of breathing with a
central apnea or hypopnea at the nadir of ventilatory effort. In
patients with heart failure, CSR is believed to result from a
high-gain ventilatory control system (increased hypercapnic
responsiveness) combined with a prolonged circulation time
(15,36). This combination leads to unstable ventilatory con-
trol and this particular pattern of periodic breathing. Idio-
pathic CSA (37) also is characterized by unstable ventilation,
which is due to a very steep ventilatory response to hyper-
capnia. Unstable ventilatory control in patients with both
CSR and idiopathic CSA can promote obstructive events
(apneas and hypopneas) in an individual with a collapsible
pharyngeal airway resulting from diminished upper airway
muscle activation at the nadir of the cycling respiration. Thus,
both central and obstructive events are commonly seen in
these patients, as discussed later.
The diagnosis of CSA may not be readily recognized by the
clinician and currently requires a full-night polysomnogram to
determine the frequency and pattern of central apnea (Table 3).
Simplified monitoring systems or oximetry alone in the diagno-
sis of CSA has not been broadly accepted; full-night polysom-
nography remains the standard. Some patients with heart failure
will demonstrate a periodic breathing pattern even during wake-
fulness and exercise (38,39). In this case, a polysomnogram is
often helpful to exclude concurrent obstructive apnea and to
guide treatment for the nocturnal periodic breathing.
Obstructive Sleep Apnea
Epidemiology
The high prevalence and wide spectrum of severity of OSA in
adults have been well documented by several population-
Figure 2. Schematic outlining possible
mechanisms underlying development of
CSA and the possible feedback from CSA
resulting in exacerbation of heart failure (16).
Reproduced with permission.
Table 3. Central Sleep Apnea
Signs, symptoms, and risk factors
Congestive heart failure
Paroxysmal nocturnal dyspnea
Witnessed apnea
Fatigue/hypersomnolence
Other signs and symptoms include male gender, older age, mitral
regurgitation, atrial fibrillation, CSR while awake, periodic breathing
during exercise, hyperventilation with hypocapnia
Screening and diagnostic tests
Overnight oximetry
Ambulatory (unattended) polysomnography
In-hospital (attended) polysomnography
Treatment options
Optimize treatment of heart failure
Positive airway pressure
Supplemental oxygen
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based cohort studies conducted in the United States, Europe,
Australia, and Asia. Although measurement techniques and
definitions have varied, most of these studies have shown that
1 in 5 adults has at least mild OSA (eg, AHI 5) and 1 in
15 has moderate or severe OSA (eg, AHI 15). Two
population studies with AHI measured longitudinally have
shown significant progression in OSA over time. In the
Wisconsin Sleep Cohort (40), the mean 8-year increase in
AHI was greatest for habitual snorers compared with nonha-
bitual snorers, those with body mass index (BMI) 30 versus
30 kg/m2, and those 45 to 60 versus 30 to 45 years of age
at baseline. In the Cleveland Family Study, the change in
median AHI was similarly highest for those 41 to 54 versus
11 to 40 and 54 years of age and BMI 31 versus 31
kg/m2 (41).
However, 85% of patients with clinically significant and
treatable OSA have never been diagnosed, and referral popula-
tions of OSA patients represent only the “tip of the iceberg” of
OSA prevalence (42,43). In addition to emphasizing the large
burden of untreated OSA in the general population, the low level
of medical detection demands caution in generalizing observa-
tions of OSA patients diagnosed in sleep clinics to cardiovascu-
lar disease patients with occult OSA. Understanding predictors
of OSA free from sleep clinic referral bias is necessary to
recognize cardiovascular disease patients likely to have OSA.
When OSA was initially being documented as a diagnosable
condition, patients were collectively described as “Pickwickian”:
morbidly obese, sleepy, middle aged, and male. This stereotype
has undoubtedly influenced case finding and led to an overrep-
resentation of these characteristics in OSA patient populations.
Large studies of OSA detected in population-based screening
have shown that although male sex and obesity are clearly risk
factors for OSA (associated with 2- and 4-fold-higher preva-
lences, respectively), clinically significant OSA is not rare in
women or in nonobese persons and is even more common in
older age compared with middle age. Furthermore, in contrast to
the high prevalence of pathological sleepiness in OSA patient
populations, excessive daytime sleepiness and OSA are not
strongly correlated in general population studies (40,44,45).
Few studies characterizing OSA in cardiovascular patients
have been conducted. Available data indicate that OSA
prevalence is 2 to 3 times higher than in reference populations
without cardiovascular disease (11,46). Risk factors for un-
diagnosed OSA in heart failure patients may differ from those
based on observations of other OSA patients. In 450 heart
failure patients referred for polysomnography, the odds ratio
(OR) for OSA with male gender (OR, 2.8) was similar to that
seen in population studies (47). However, for men, only
obesity was significantly related to OSA, and for women, age
but not obesity was related to OSA. Of particular importance,
and for reasons that are not well understood, OSA may not
manifest with sleepiness in heart failure patients (48,49).
Population-based epidemiology studies and observations of
OSA patients have consistently shown the prevalence of hyper-
tension, type II diabetes, cardiovascular disease, and stroke to be
higher in people with OSA (7,10,46,50–57). Because all these
conditions are chronic, have multifactorial and overlapping
origins, and have long latent periods before symptoms appear,
identifying a causal role of OSA is difficult. In cross-sectional
studies that rely on a diagnosis of cardiovascular disease as the
end point, subjects with preclinical and asymptomatic disease
will be missed. Risk factors or causes common to both condi-
tions, including male sex, age, overweight, central body fat
deposition, alcohol, smoking, and lack of exercise, explain some
but not all of the correlation between OSA and cardiovascular
disease. In addition to concern about these as “confounding”
factors in investigating the independent role of OSA in promo-
tion of cardiovascular disease, there also is interest in the
concurrent presence of the constellation of OSA, cardiovascular
disease, and their common risk factors (10,51,58).
Before widespread use of continuous positive airway
pressure (CPAP) as a standard of care (59,60), patients with
OSA treated conservatively had increased mortality com-
pared with OSA patients who had undergone tracheostomy,
even though the latter group had a higher BMI (34 versus 31
kg/m2) and more severe OSA (AHI, 69 versus 43) (61). Most
deaths were cardiovascular. Similarly, another study showed
that mortality in OSA patients with an AHI20 was 0% over
8 years in those treated with tracheostomy or nasal CPAP,
significantly lower than those treated with uvulopalatopha-
ryngoplasty or those left untreated (62). Population-based
longitudinal studies with objective measurement of OSA,
initiated over the past 15 years, have begun to clarify the
nature of the OSA–cardiovascular disease link. An 11-year
follow-up of older residents in San Diego (Calif) showed the
mortality rate for cardiovascular disease to be higher for those
with OSA (35% for AHI 15, 56% for AHI 15) (46).
Prospective analyses of the Wisconsin Sleep Cohort Study
indicate that OSA increases the risk of incident hypertension
(56). Snoring, as a marker of OSA, predicted hypertension,
cardiovascular disease, and type II diabetes in the Nurses
Health Study (50,53,54) as did short sleep duration (63). In
1995, the Sleep Heart Health Study was initiated to investi-
gate the role of OSA in cardiovascular disease using in-home
polysomnography; baseline and follow-up data have been
collected on a sample of 3000 adults, and longitudinal
analyses are now underway (64).
Clinical Presentation
OSA affects male individuals more commonly than female
individuals and may present with a number of signs and
symptoms suggestive of the disorder (Table 1) or with no
symptoms whatsoever. However, clinical judgment ulti-
mately must be used in deciding which patients deserve
further evaluation. For example, virtually all patients with
OSA snore, but not all snorers have sleep apnea.
Signs and symptoms apply to large patient cohorts that
include patients with and without cardiovascular disease,
raising the question of whether there are specific indications
for apnea evaluation in patients with cardiac or vascular
disease. The answer is likely “yes,” given the high prevalence
of OSA in hypertension, including resistant hypertension
(requiring 3 medications), atrial fibrillation, and nocturnal
angina. Both OSA and CSA occur commonly in patients with
heart failure and may contribute to disease progression.
Treating sleep apnea may be particularly relevant in these
patients, and the diagnosis should be carefully considered.
However, this does not imply that all patients with hyperten-
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sion, atrial fibrillation, nocturnal angina, or heart failure
should undergo formal testing for sleep apnea. If other
indicators also are present (witnessed apneas, disruptive
snoring, obesity, waking hypersomnolence) or if the cardio-
vascular condition is refractory to standard therapy, there
should be a low threshold for pursuing this diagnosis.
Early studies suggested the interesting and clinically rele-
vant possibility that OSA may have more deleterious cardio-
vascular consequences in subjects 50 years of age (62).
This concept has found support in more recent data showing
that younger people with OSA may be more likely to have
hypertension (65) and atrial fibrillation (66) and to suffer
greater all-cause mortality (67). These data may argue in
favor of a more aggressive diagnostic and therapeutic strategy
in younger and middle-aged subjects with OSA. Differential
effects of race, gender, and other demographics also merit
consideration and require further investigation.
Mechanisms of Disease and Associated
Cardiovascular Risk
Obstructive apneas may induce severe intermittent hypox-
emia and CO2 retention during sleep, with oxygen saturation
sometimes dropping to 60%, disrupting the normal struc-
tured autonomic and hemodynamic responses to sleep (68).
Apneas can occur repetitively through the night and are
accompanied by chemoreflex-mediated increases in sympa-
thetic activity to peripheral blood vessels and consequent
vasoconstriction (69,70). Toward the end of apneic episodes,
blood pressure (BP) can reach levels as high as 240/130
mm Hg (71). This level of hemodynamic stress occurs at a
time of severe hypoxemia, hypercapnia, and adrenergic acti-
vation. Nocturnal apneas initiate a range of pathophysiolog-
ical mechanisms outlined below, which may act to promote
cardiac and vascular disease (Figure 3).
Sympathetic Activation
Heightened sympathetic drive elicited by recurrent apneas
during sleep persists into normoxic daytime wakefulness
(71). Sympathetic traffic to peripheral blood vessels is in-
creased even in people with OSA who are otherwise healthy
independently of obesity (72). Patients with OSA also have
faster heart rates during resting wakefulness, suggesting that
there also is increased cardiac sympathetic drive (73). The
mechanisms for this heightened sympathetic activation are
not known. One possibility is that increased chemoreflex gain
in OSA results in tonic chemoreflex activation even during
normoxia, with consequent increased sympathetic activity.
Administration of 100% oxygen (to eliminate tonic chemore-
flex drive) significantly lowers sympathetic activity, heart
rate, and BP in OSA patients during daytime wakefulness (74).
Cardiovascular Variability
Compared with similarly obese control subjects, resting
awake OSA patients have diminished heart rate variability
and increased BP variability (73). In patients with cardiovas-
cular disease, reduced heart rate variability is associated with
poorer outcomes (75–77). The Framingham Heart Study has
implicated lower heart rate variability as a precursor to the
development of future hypertension (78), and increased BP
variability has been implicated in increased risk of end-organ
damage in patients with hypertension (79).
Vasoactive Substances
Recurrent hypoxemic stress induces increased release of
vasoactive and trophic substances that may elicit vasocon-
striction persisting for hours. Endothelin is released in cell
culture during hypoxia (80). In patients with OSA, untreated
severe sleep apnea lasting several hours results in increased
endothelin levels, which fall after 4 hours of treatment with
CPAP (81). More recent data support a role for endothelin in
raising BP in OSA patients (82). A positive correlation also
has been reported between aldosterone and OSA severity, but
this correlation was true only for patients with resistant hy-
pertension and was not evident in normotensive controls (83).
Inflammation
Hypoxemia appears to be an important mechanism for trigger-
ing systemic inflammation. Healthy subjects at altitude manifest
increased levels of inflammatory molecules such as interleukin-6
and C-reactive protein (84). Sleep deprivation also may trigger
systemic inflammation (85,86). The combination of repetitive
Figure 3. Schematic outlining proposed
pathophysiological components of OSA,
activation of cardiovascular disease mecha-
nisms, and consequent development of
established cardiovascular disease.
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hypoxemia and sleep deprivation in OSA patients may be
associated with increased levels of plasma cytokines, adhesion
molecules (87,88), serum amyloid A (89), and C-reactive protein
(88,90–92). Although the increase in C-reactive protein in OSA
appears to be independent of adiposity (92), this question
remains controversial (93). There also is evidence for enhanced
leukocyte activation in OSA (94,95). Monocytes from OSA
patients bind more actively to cultured endothelial cells than do
monocytes from control subjects, and treatment by CPAP
attenuates this monocyte binding (94). Ryan et al (96), reported
that in vitro, intermittent hypoxia and reoxygenation selectively
activated the proinflammatory transcription factor nuclear
factor-B, whereas the adaptive regulator hypoxia-inducible
factor-1was not activated. Related studies in OSA patients also
noted increased circulating tumor necrosis factor- levels
(which decreased after 6 weeks of CPAP) but not in erythropoi-
etin and concluded that the intermittent hypoxia of OSA selec-
tively activated inflammatory over adaptive pathways.
Oxidative Stress
The repetitive hypoxemia and reoxygenation that characterize
sleep in OSA patients may be implicated in the triggering of
oxidative stress mechanisms (97–99). Some studies have re-
ported increased levels of thiobarbituric acid reactive substances,
isoprostanes, and oxidized low-density lipoprotein in OSA
(100), although these changes have not been confirmed in other
studies (101). Circulating free nitrotyrosine, a marker of nitro-
sative oxidative stress, is not elevated in OSA patients (102).
Microarray measures of gene transcription in OSA subjects
before and after sleep suggest the activation of several mechanisms
that may modulate and adapt to any increased reactive oxygen
species developing in response to overnight hypoxemia (103).
Endothelial Dysfunction
Systemic inflammation, sympathetic activation, pressor surges,
and oxidative stress may all contribute to the development of
endothelial dysfunction. However, evidence for endothelial dys-
function in OSA patients has not been consistent, and studies
have been limited to relatively modest numbers of subjects. A
selective impairment of resistance vessel (small vessel) endothe-
lial function but not conduit vessel (brachial artery) endothelial
function was reported in otherwise healthy OSA patients com-
pared with similarly obese subjects proven to be free of sleep
apnea (81). However, other studies using correlative approaches
in patients with comorbidities reported an inverse relationship
between brachial artery flow-mediated dilation and sleep apnea
severity (104). Conflicting findings with regard to resistance
vessel endothelial function in OSA (105,106) speak to the
importance of careful exclusion of comorbidities in studies of
OSA patients. Nevertheless, recent data suggest not only that
conduit vessel endothelial function may be impaired in OSA but
also that the impairment may be related to endothelial cell
apoptosis and that treatment with CPAP may improve endothe-
lial function (107,108).
Insulin Resistance
Increased catecholamines, sleep deprivation (109), and other
pathophysiological characteristics of OSA may be associated
with insulin resistance. Indeed, data from several studies
suggest an association between OSA and glucose intolerance
independently of BMI (110–112). Vascular and other adverse
effects of insulin resistance may contribute to cardiovascular
disease in OSA. However, although some studies suggest that
CPAP therapy may reduce insulin resistance in OSA (113), a
systematic review of 24 earlier reports, while confirming a
probable independent link between SDB, glucose intolerance,
and insulin resistance, also concluded that studies on the
treatment of SDB with CPAP yielded inconsistent results and
did not reveal an improvement in the metabolic disturbance
after treatment (114). Finally, related metabolic dysregulation
such as leptin resistance and the metabolic syndrome also
have been linked to OSA (51,115).
Thrombosis
OSA also been associated with increased platelet activation,
increased fibrinogen, and other potential markers of throm-
botic risk (116). However, additional studies are needed to
more definitively evaluate the role of hemostatic mechanisms
and to confirm any hypercoagulable state in OSA (117).
Intrathoracic Pressure Changes
Obstructive apnea causes repetitive forced inspiration against
a closed upper airway (the Mueller maneuver), which gener-
ates very substantial negative pressures in the chest cavity, to
levels approaching 65 mm Hg. This negative intrathoracic
pressure increases transmural gradients across the atria,
ventricles, and aorta (118,119), and disrupts ventricular
function (118) and autonomic and hemodynamic stability
(120). Consequences may include increased wall stress,
increased afterload, increased atrial size (121,122), impaired
diastolic function (121,123), thoracic aortic dilation, and
propensity toward dissection (124). Whether repetitive noc-
turnal increases in transmural gradients may contribute in the
longer term to ventricular hypertrophy and remodeling and
associated clinical consequences remains to be established.
Cardiovascular Diseases and OSA
Hypertension
The Prevalence of OSA in Hypertension
Both OSA and hypertension are common, and many individ-
uals have both conditions. About 50% of OSA patients are
hypertensive (125), and an estimated 30% of hypertensive
patients also have OSA, often undiagnosed (126–130). In the
Wisconsin Sleep Cohort Study, Hla et al (131) and Young et
al (132) found a linear relationship between 24-hour BP and
AHI that was independent of confounding factors such as
BMI. Those patients with an attenuated nocturnal BP decline
(nondippers) may be more likely to have coexisting OSA
(133). Nocturnal sympathetic activation and consequent
higher sleep-related BPs (71) may attenuate the nocturnal
dipping of BP. A blunted nocturnal BP decline has been
associated with greater leukoaraiosis (white matter disease)
(134). Recent data in almost 4000 subjects show an increase
in all-cause mortality in those with a blunted (hazard ratio,
1.30; 95% CI, 1.00 to 1.69) or absent (hazard ratio, 1.96; 95%
CI, 1.43 to 2.96) nocturnal BP fall (135).
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OSA and the Origin and Progression of Hypertension
Animal studies in rats and dogs have identified possible
mechanisms by which OSA might lead to hypertension such
as intermittent hypoxemia, chemoreceptor stimulation (136),
sympathetic activation (136,137), and the renin-angiotensin
system. In dogs, obstructing a tracheostomy to simulate apnea
causes an acute increase in BP of20 mm Hg, which persists
for several hours and is exacerbated by prior sleep depriva-
tion (138). The BP increase can be attenuated by pharmaco-
logical blockade of the autonomic nervous system with
hexamethonium, indicating that it is mediated by the sympa-
thetic nervous system rather than by mechanical factors
related to changes in intrathoracic pressure. Longer-term (1 to
3 months) maintenance of repetitive nocturnal airway occlu-
sion to mimic OSA more closely resulted in daytime hyper-
tension in a dog model of OSA. Repetitive nocturnal arousal
resulting from an acoustic stimulus delivered without airway
occlusion did not elicit daytime hypertension, underscoring
the importance of the hypoxemic stress (139).
OSA has been proposed as an independent risk factor for the
development of essential hypertension because it can precede
and predict the onset of hypertension. This has been demon-
strated by the Wisconsin Sleep Cohort Study, which noted a
consistent OSA-BP dose-response relationship, even after con-
trolling for age, sex, BMI, and antihypertensive medications
(56). Effects of OSA on hypertension may be especially evident
in middle-aged compared with older subjects, and OSA may
predominantly raise systolic BP (65). Although OSA has also
been implicated in pregnancy-associated hypertension (140–
142), the etiologic interactions need to be more clearly defined.
In the third trimester of pregnancy, snoring is increased and the
upper airway diameter is narrow compared with postpartum
(143). The severity of sleep apnea and the associated BP
responses measured in the third trimester improve significantly
(P0.03) after parturition, further supporting the concept that
pregnancy may exacerbate sleep apnea (144).
To determine the interaction between OSA in patients with
drug-resistant hypertension, defined as a clinic BP of 140/
90 mm Hg while taking a combination of 3 antihyperten-
sive drugs titrated to maximally recommended doses, Logan
et al (145) noted that the prevalence of OSA, defined as an
AHI of 10, was 83%. In another study (146), sleep apnea
was found to be an independent predictor of uncontrolled
hypertension in patients 50 years of age. Increased aldoste-
rone has been suggested as a possible contributor to resistant
hypertension in sleep apnea (83,147,148).
The weight of evidence has led the most recent Joint
National Committee on the Detection and Management of
Hypertension to identify OSA as an important identifiable
cause of hypertension (149).
Treatment of OSA: Effects on Hypertension
Effective treatment of OSA by CPAP has been shown to
markedly and acutely decrease BP and sympathetic traffic
during sleep (71). Chronic effects of CPAP treatment are less
clear because of the relative lack of robust longitudinal
controlled studies. Many of the early studies had no control
group or did not include 24-hour ambulatory BP recording. In
an observational study of CPAP-treated versus CPAP-
intolerant patients, no significant differences were evident in
the development of new cases of hypertension in the treated
versus untreated group (150). In addition, short-term CPAP
treatment in patients with well-controlled hypertension did
not elicit any BP improvement (151).
Recent studies have more often been placebo controlled
(152–154), comparing CPAP with either placebo pills or with
sham CPAP. BP reduction is either modest or absent in normo-
tensive subjects but may be more evident in hypertensives.
Three studies reporting a fall in BP used subtherapeutic (sham)
CPAP in the control arm. The largest of all the studies (118
patients) (155) reported a reduction of 3.4/3.3 mm Hg (slightly
larger during the day than during the night). In patients taking
antihypertensive drugs, the 24-hour mean BP fall was about
twice as large (6.7 versus 3.3 mm Hg), and the benefit was
greater in patients with more severe OSA. The second study
(156) found that both placebo CPAP and real CPAP reduced
daytime BP equally well but that only real CPAP lowered the
nighttime pressure. The third study found that therapeutic CPAP
lowered daytime BP by 10.3/11.2 mm Hg more than subthera-
peutic CPAP and nighttime pressure by 12.6/11.4 mm Hg (157).
However, in another study comparing the effects of CPAP in
hypertensives with and without OSA, CPAP lowered the night-
time pressure in those with OSA but had no effect on the
daytime pressure (158). A randomized placebo-controlled study
of 1 month of therapeutic CPAP versus subtherapeutic CPAP on
ambulatory BP showed no significant changes in systolic,
diastolic, daytime, or nighttime BP (159).
Finally, 3 meta-analyses of the effect of treating OSA with
CPAP on BP have been published recently. One was re-
stricted to trials involving ambulatory BP recordings (160),
the other to trials with treatment duration of 2 weeks. The
second included OSA patients with heart failure and OSA
patients with normal systolic function (161). Overall, the net
reduction in BP (2 mm Hg) was significant but modest. A
third meta-analysis (162) included randomized controlled
trials that reported systolic and diastolic BPs before and after
CPAP/control and noted modest (1.5 mm Hg) decreases in
both systolic BP (P0.23) and diastolic BP (P0.06). In 6
trials that evaluated more severe OSA (AHI 30), CPAP
reduced systolic BP by 3 mm Hg (P0.10) and diastolic
BP by 2 mm Hg (P0.05).
Considered together, these studies suggest that there are
moderate and variable effects of CPAP on BP in patients with
OSA. Patients with more severe OSA, difficult-to-control hy-
pertension, and better CPAP compliance may have more sub-
stantial BP reduction with CPAP. The greater changes in BP
seen in 1 study (157) may have a number of explanations: The
duration of CPAP use was longer, the subjects were more
hypertensive, and the device used to record BP may have caused
less interference with sleep. CPAP also may improve BP control
in patients with refractory hypertension (163). In those hyper-
tensive patients who cannot tolerate CPAP, oral appliances that
effectively attenuate OSA also may lower BP (164,165).
Treatment of Hypertension: Effects on OSA
It is likely that antihypertensive drugs will have different
effects in patients with OSA, but there are few systematic
data. Clonidine has been reported to suppress rapid eye
693JACC Vol. 52, No. 8, 2008 Somers et al.
August 19, 2008:686–717 AHA/ACC Sleep Apnea and Cardiovascular Disease
movement (REM) sleep and hence to suppress the apneas
occurring during REM, which resulted in lessened nocturnal
hypoxemia (166). Cilazapril, an angiotensin-converting en-
zyme inhibitor, had no effect on the AHI but lowered BP
during sleep (167), whereas celiprolol, a -blocker, decreased
daytime BP but had relatively little effect during the night
(168). A comparison of the effects of 5 commonly used
antihypertensive drugs (atenolol, amlodipine, enalapril, losar-
tan, and hydrochlorothiazide) on BP and sleep architecture
(169) showed no effect on the severity of the sleep apnea. The
drugs had similar effects on daytime BP, although atenolol
reduced the nocturnal pressure slightly more than the other
drugs. Thus, there is no current evidence that any specific
antihypertensive drug has direct effects on attenuating sleep
apnea severity. Conversely, a recent report suggests that
cough and rhinopharyngeal inflammation induced by
angiotensin-converting enzyme inhibitors may worsen the
AHI, which decreases after discontinuation of the drug (170).
Heart Failure
Prevalence of OSA in Heart Failure
In 2 large case series, OSA was detected in 37% of 450 (47)
and 11% of 81 (48) patients with heart failure resulting from
systolic dysfunction who were referred for polysomnography.
Only a minority of such patients complain of excessive
daytime sleepiness (48,49). The prevalence of OSA in heart
failure was greater in men (38% versus 31%; P0.005) (47).
In men, the main risk factor for OSA was obesity, whereas in
women, it was older age (47).
However, these prior descriptions of disease frequency are
limited by referral bias. To address this concern, Wang et al
(171) performed a prospective study in which polysomnog-
raphy was performed on all consenting patients newly re-
ferred to a tertiary hospital heart failure clinic for assessment
and management. Of the 218 patients studied, OSA with an
AHI 15 was detected in 26%. OSA also has been noted in
50% of heart failure patients with preserved systolic func-
tion (172). Three months of CPAP was reported to attenuate
abnormalities in diastolic function (123), suggesting a poten-
tial etiologic role of OSA in diastolic heart failure.
OSA and the Origin and Progression of Heart Failure
The most direct mechanism by which long-standing OSA might
induce left ventricular systolic dysfunction is by raising BP.
Hypertension is the most common risk factor for ventricular
hypertrophy and failure (173). Nocturnal oxygen desaturation is
an independent predictor of impaired ventricular relaxation
during diastole (174). In the Framingham study, increased BMI,
an important predisposing factor for OSA, also was associated
with greater risk of developing heart failure (175).
It has been suggested that left ventricular hypertrophy is
more closely linked to hypertension during sleep than during
wakefulness (176). Thus, the higher nocturnal BP in hyper-
tensive patients with OSA than in those without (133) may
place such individuals at greater risk in the long term for left
ventricular hypertrophy and failure. In patients with heart
failure, the coexistence of OSA may be associated with
higher sympathetic nerve activity and higher systolic BP
during wakefulness, despite more intense antihypertensive
therapy (177). Responses to cytokines, catecholamines, en-
dothelin, and other growth factors produced in OSA also may
contribute to ventricular hypertrophy independently of hyper-
tension. Indeed, there is evidence to suggest that OSA is
associated with altered cardiac structure and function
(121,123,178,179) and that some of these changes may be
reversible with effective CPAP treatment.
OSA could potentially contribute to the progression of
heart failure through several pathological mechanisms: 1) by
eliciting greater sympathetic outflow to the heart, kidney, and
resistance vessels during wakefulness and sleep; 2) by in-
creasing left ventricular afterload both acutely and chroni-
cally; 3) by inducing hypoxia and secondary increases in right
ventricular afterload; and 4) by increasing the risk of myo-
cardial infarction (180). Recent studies using tissue Doppler
imaging during dobutamine stress echocardiography have
also raised the possibility that patients with OSA have
depressed myocardial contractile reserve (181). Finally, data
obtained in heart failure patients with OSA, using cardiac
C-11 acetate positron emission tomography, suggest a poten-
tial role for CPAP therapy in modulating myocardial ener-
getics and metabolic efficiency in the failing heart (182,183).
Heart failure patients with coexisting OSA are exposed to
adrenergic activation during sleep (5) and when awake. BP
rises above, rather than descends below, waking values (184).
Thus, myocardial oxygen demand increases at times of
recurrent hypoxia. Consequent metabolic mismatch could
directly reduce myocardial contractility (185). These stresses
may place the patient with OSA and heart failure at greater
risk of myocardial ischemia (186), worsening ventricular
function, arrhythmias, and death.
The repetitive generation of up to 65 mm Hg intratho-
racic pressure against the occluded pharynx induces striking
hemodynamic and autonomic responses (120) and is a cardiac
load unique to OSA (187). When subjected to such abrupt
increases in left ventricular transmural pressure (ie, afterload)
and therefore myocardial oxygen demand, patients with
systolic heart failure experience more profound and pro-
longed reductions in stroke volume (188) and greater reflex
increases in central sympathetic outflow (189) than control
subjects with normal left ventricular function. Because these
obstructive events may occur hundreds of times over the
course of the night, these abrupt increases in left ventricular
transmural pressure could play an important role in the
development of myocardial ischemia, myocyte slippage, con-
tractile dysfunction, and ventricular dilation (190).
However, yet to be established is whether OSA can cause
heart failure. In addition, whether the presence of OSA in
heart failure accelerates mortality remains unclear. In 78
patients with congestive heart failure being evaluated for
possible heart transplantation, the presence of OSA did not
affect long-term (52 months) survival (191). On the other
hand, more recent data suggest that the presence of untreated
OSA (AHI 15) in patients with heart failure is associated
with an increased risk of death compared with patients with
an AHI 15 independently of confounding factors (171).
Treatment of OSA: Effects on Heart Failure
OSA patients are advised to reduce weight and to abstain from
alcohol and sedatives that predispose to pharyngeal collapse
694 Somers et al. JACC Vol. 52, No. 8, 2008
AHA/ACC Sleep Apnea and Cardiovascular Disease August 19, 2008:686–717
during sleep; these general measures may reduce the severity of
heart failure and the severity of OSA (192,193). There have been
no controlled studies of mandibular advancement devices or
upper airway surgery involving OSA patients with heart failure.
To date, randomized trials in heart failure have evaluated the
impact of treating OSA on surrogate cardiovascular end points
such as left ventricular ejection fraction rather than on hospital-
ization rates and mortality. Acutely, treatment of coexisting
OSA by CPAP can eliminate recurrent hypoxia and reduce
nocturnal BP and heart rate (184). The first study to examine the
effects of CPAP on left ventricular function during the awake
state was uncontrolled. Eight patients with idiopathic dilated
cardiomyopathy and coexisting OSA were studied. After 1
month of CPAP, mean left ventricular ejection fraction increased
from 37% to 49% and dyspnea was reduced significantly (187),
but these responses dissipated within a week of withdrawal of
CPAP. In the first randomized trial involving 24 patients with
heart failure (mean left ventricular ejection fraction 45%) and
moderate to severe OSA (mean AHI 20), 30 days of CPAP
lowered daytime heart rate and systolic BP and increased
ejection fraction by 9%. In contrast, there was no change in any
of these variables in the 12 patients in the control group (194). In
a second larger randomized cohort with heart failure (mean left
ventricular ejection fraction 55%) and OSA (mean AHI 5),
there was a more modest 5% increase in ejection fraction after 3
months of CPAP treatment in the 71% of randomized patients
who completed this trial (195). Mean BP did not fall. It is
notable, however, that a third randomized study, and the only
one that used a crossover design, showed no effects of autoti-
trating CPAP compared with subtherapeutic CPAP on peak V˙ O2,
6-minute walk distance, plasma catecholamines, or left ventric-
ular ejection fraction, although there was a decrease in daytime
sleepiness (196). Differences in methodology and in patient
characteristics may help explain some of the inconsistent find-
ings from studies evaluating OSA treatment in congestive heart
failure patients (197). Recent observational data suggest a trend
(P0.07) to a lower mortality rate in heart failure patients with
CPAP-treated OSA compared with untreated OSA (171). How-
ever, whether CPAP treatment of patients with OSA and heart
failure leads to mortality benefit has yet to be tested in a
randomized clinical trial (198).
Treatment of Heart Failure: Effects on OSA
Fluid retention in heart failure would be expected to poten-
tiate airway obstruction. Prolonged recumbent posture, as
occurs during sleep, would predispose to congestion of upper
airway soft tissue structures. Consequent airway narrowing
and increased airway resistance would require increased
generation of negative intrathoracic pressures to maintain
flow, thus theoretically predisposing to upper airway occlu-
sion (199). Indeed, in healthy volunteers, rapid displacement
of 340 mL of fluid from the legs to the upper body, elicited
by lower-body positive pressure, increased neck circumfer-
ence and pharyngeal resistance to airflow, and reduced upper
airway cross-sectional area (200,201). Hence, decreased in-
travascular volume and attenuated venous congestion result-
ing from heart failure treatment could potentially reduce OSA
severity. However, there is no systematic evidence that
specific drugs used to treat heart failure have any direct
influence on the severity of OSA (169), apart from an increase
in AHI reported in the setting of cough and airway inflam-
mation with angiotensin-converting enzyme inhibitors (170).
Stroke
The Prevalence of OSA in Stroke
Studies evaluating the prevalence of OSA in patients with
stroke are inherently biased in terms of studying only stroke
survivors. Other limitations include selection criteria such as
evaluation only of those transferred to a rehabilitation unit.
Furthermore, because vascular injury to the respiratory and
other centers may precipitate CSA and/or OSA, poststroke
sleep apnea characteristics cannot be assumed to have been
present before stroke. Sleep breathing characteristics also
may change significantly in the poststroke period.
Several studies have noted a high prevalence of sleep
apnea in subjects studied shortly after stroke (202,203).
However, a recent study from Sweden noted that of 132
patients admitted for in-hospital rehabilitation who under-
went overnight cardiorespiratory sleep monitoring, only 23
patients had OSA, 28 had CSA, and 2 patients had mixed
apnea (204). Body position is important in interpreting
polysomnographic findings after stroke because poststroke
AHI often is highest when patients are maintained in the
recumbent position, especially within the first 24 hours of
stroke (205,206). Bassetti and Aldrich (206) found an AHI
10 in 62% of transient ischemic attack patients compared
with 12% of control subjects, suggesting that SDB may
precede the onset of stroke. This was not confirmed in a
case-control study of 86 transient ischemic attack patients, in
whom the likelihood of sleep apnea was similar to that in
control subjects (207).
OSA and the Origin and Progression of Stroke
The concept of sleep apnea as a risk factor for primary
ischemic stroke is mostly inferential and derives from evi-
dence implicating sleep apnea in hypertension and heart
disease, both of which are risk factors for stroke. Mechanisms
that have been implicated in any increased risk of stroke in
OSA include BP swings, reduction in cerebral blood flow,
altered cerebral autoregulation, impaired endothelial func-
tion, accelerated atherogenesis, and prothrombotic and proin-
flammatory states. For example, blunted cerebral blood flow
in response to hypoxia in patients with OSA has been
described and has been reported to normalize after 4 to 6
weeks of CPAP therapy (208). Epidemiological studies sug-
gest that habitual snoring, a possible marker for OSA, is a risk
factor for brain infarction independently of confounding
factors such as obesity and age (209). Similarly, excessive
daytime sleepiness identified with the Epworth Sleepiness
Score was significantly associated with stroke (OR, 3.07;
95% CI, 1.65 to 6.08) in a case-control study of 181 patients
(210). The authors suggested that daytime sleepiness was
possibly the consequence of OSA. Some studies (211) noted
a high prevalence of leukoaraiosis in those stroke patients
who had sleep apnea, suggesting that OSA may lead to
leukoaraiosis and consequently to stroke. In a cross-sectional
study of Japanese men, brain magnetic resonance imaging
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revealed silent brain infarction in 25% of patients with
moderate to severe OSA but in only 8% of patients with mild
OSA and in 6% of control subjects, suggesting that OSA may
elicit early and asymptomatic cerebrovascular damage (88).
Available data often are limited by the use of oximetry rather
than complete polysomnographic studies and by the relatively
small numbers of subjects studied. Furthermore, the broad
spectrum of comorbidities and pharmacological intervention
in poststroke patients constrains identification of any inde-
pendent premorbid etiologic role of sleep apnea.
In a cross-sectional analysis of 6000 subjects from the
Sleep Heart Health Study, the OR of prevalent stroke was
modestly greater (1.58) among those subjects with sleep
apnea with an AHI 11 (57). More recent data obtained in
large population samples have provided newer insights into
sleep apnea as a potential cause of stroke. SDB with an AHI
of 20 was associated with an increased risk of suffering a
first-ever stroke over a 4-year follow-up in a cross-sectional
analysis. However, in the prospective longitudinal analysis of
these data, after adjustment for age, sex, and BMI, the OR
was still elevated but no longer statistically significant (OR,
3.08; 95% CI, 0.74 to 12.81; P0.12) (212).
Recent 10-year follow-up data of patients with stroke show
an increased risk of death in those patients with OSA (adjusted
hazard ratio, 1.76; 95% CI: 1.05 to 2.95; P0.03) that is
independent of age, sex, BMI, smoking, hypertension, diabetes
mellitus, atrial fibrillation, Mini-Mental State Examination
Score, and Barthel Index of Activities of Daily Living. In
contrast, CSA was not accompanied by increased poststroke
mortality compared with control subjects (adjusted hazard ratio,
1.07; 95% CI: 0.65 to 1.76; P0.80) (204). In an analysis of the
effects of OSA on the composite outcome of stroke or death
(213), another study reported that increasing severity of sleep
apnea was associated with an increased risk of stroke or death
independently of age, sex, race, smoking, alcohol, BMI, diabe-
tes, hyperlipidemia, atrial fibrillation, and hypertension. Al-
though many patients were receiving some type of treatment for
sleep apnea over the course of this observational study, the
hazard ratio for those with severe OSA (AHI 36) was 3.3
(95% CI, 1.74 to 6.26) (213). This high risk of stroke or death
even in the setting of apparent treatment for OSA suggests that
the risk would have been even greater in the absence of
treatment; an alternative that has to be considered is that
treatment of OSA may have had only modest, if any, beneficial
effects on the prevention of stroke or death (214).
Treatment of OSA: Effects on Stroke
The application of noninvasive positive airway pressure venti-
lation offers patients with sleep apnea a window of opportunity
to increase the rehabilitation potential after stroke. Unfortu-
nately, CPAP compliance has not been good in patients recov-
ering from stroke, and beneficial effects have not been con-
firmed (215). Tolerability and compliance with CPAP after
stroke may be limited compared with patients without stroke
(216). In a prospective study of patients after acute ischemic
stroke, Bassetti et al (203) found that only 15% of those with
sleep apnea continued CPAP chronically. On the other hand,
Wessendorf et al (217) prospectively studied 105 stroke patients
with OSA to evaluate the effectiveness and acceptance of
treatment with CPAP. They found that 70% of patients contin-
ued treatment at home. The authors concluded that stroke
patients with OSA can be treated effectively with CPAP and
show improvement and acceptance similar to those of OSA
patients without stroke. Whether patients with stroke and OSA
benefit from treatment with CPAP remains to be determined.
Several studies suggest that OSA in the poststroke patient
reduces motivation, decreases cognitive capacity, and may
increase the risk of recurrent stroke and death. Dyken et al
(218) noted that patients after stroke have a high prevalence
of OSA and that those stroke patients with OSA had a
markedly diminished poststroke survival. Similar findings
regarding survival and limited rehabilitation success
(219,220) have been reported by other investigators. Direct
studies of the interaction between sleep apnea and rehabili-
tation outcome after stroke that used overnight pulse oxime-
try to evaluate the respiratory disturbance index suggested
that hypoxic events during sleep predicted poorer recovery,
especially in patients with poor function at admission. In
polysomnographic studies of stroke patients in a rehabilita-
tion unit, a high prevalence of sleep apnea, predominantly
OSA, was accompanied by worse functional impairment and
a longer time spent in hospital and rehabilitation (221).
Effects of Stroke on Sleep Apnea
Immediately after an acute stroke, CSA may be more com-
mon than OSA (222) and may influence stroke outcome,
whereas in the postacute recovery phase and during rehabil-
itation, OSA predominates (220). The site of brain lesion,
magnitude of injury, effects on upper airway tone, effects of
supine posture during polysomnography, consequences of
transient mental obtundation, and medications may have
striking effects on the presence and severity of sleep apnea.
The prevalence of sleep apnea several months after stroke,
although still high, is less than that evident in the acute
poststroke phase (203).
Arrhythmias
Prevalence of Arrhythmias in Sleep Apnea
Cardiac arrhythmias are reportedly more frequent in persons
with OSA and increase with the number of apneic episodes
and the severity of the associated hypoxemia (223–225).
Nocturnal arrhythmias have been shown to occur in up to
50% of OSA patients. The most common arrhythmias during
sleep include nonsustained ventricular tachycardia, sinus
arrest, second-degree atrioventricular conduction block, and
frequent (2 bpm) premature ventricular contractions (226–
230). A tracheostomy can suppress these arrhythmias, except
for premature ventricular complexes (230). Controversy re-
mains as to whether OSA is a primary etiologic factor for
tachyarrhythmias because of the high incidence of cardiovas-
cular comorbidities in persons diagnosed with OSA. How-
ever, recent data from the Sleep Heart Health Study, com-
paring 228 subjects with SDB and 338 subjects without SDB,
suggested that those with severe SDB had a 2- to 4-fold-
higher risk of nocturnal complex arrhythmias. Even after
adjustment for age, sex, BMI, and prevalent coronary artery
disease, patients with SDB had increased likelihoods of atrial
fibrillation (OR, 4.02; 95% CI, 1.03 to 15.74), nonsustained
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ventricular tachycardia (OR, 3.40; 95% CI, 1.03 to 11.20),
and complex ventricular ectopy (OR, 1.74; 95% CI, 1.11 to
2.74) (231).
Bradyarrhythmias. Prolonged apnea and hypoxemia in OSA
elicit the diving reflex, which results in cardiac vagal activa-
tion, with simultaneous sympathetic activation to the periph-
eral blood vessels, including muscle, renal, and splanchnic
but not cerebral vasculature (232–234). Although the vagal
response often will elicit a discernible bradycardia, in a
minority of OSA patients (perhaps 10%), bradyarrhythmias
such as atrioventricular block and asystole may develop, even
in the absence of cardiac conduction disease. These are most
likely to occur during REM sleep and with a drop in oxygen
saturation of at least 4% (226,235). Electrophysiological
characteristics of the sinus node and atrial conduction system
in OSA subjects with nocturnal bradyarrhythmias were nor-
mal or nearly normal while awake, and CPAP reversed the
bradyarrhythmias, suggesting that OSA may have induced the
arrhythmias (234,236,237). First-line treatment of bradyar-
rhythmias in the setting of obstructive apneas and normal
conduction would consist of treatment of OSA. Data emerg-
ing from the European Multi-Center Polysomnographic
Study show a remarkably high prevalence (59%) of sleep
apnea syndrome in patients with pacemakers (238). Pacemak-
ers were reprogrammed 12 to 24 hours before polysomnog-
raphy to promote spontaneous atrial and ventricular rhythm
with respect to individual indications for pacing. Sleep apnea
syndrome was evident in 68% of patients with atrioventric-
ular block. The authors raised the question of whether
primary treatment of sleep apnea would have changed the
need for pacing in some of these patients, noted that their
patients were less symptomatic than typical sleep apnea
syndrome patients, and suggested that paced patients should
be systematically evaluated for sleep apnea because of its
potential detrimental cardiovascular effects.
Atrial Fibrillation. Hypoxemia, sympathetic activation, pressor
surges, transmural pressure changes, and systemic inflammation
that occur in OSA also may be mechanisms that predispose to
the development of atrial fibrillation. Data from Framingham
(239) and from the Danish Diet, Cancer and Health Study (240)
examining independent predictors of atrial fibrillation found
obesity to be an important marker. Sleep apnea was not ac-
counted for in either of these studies. However, after adjustment
for left atrial enlargement in the Framingham data, the effects of
obesity were no longer significant (239). Sleep apnea has been
associated with left atrial enlargement (121,122). That OSA
leads to atrial fibrillation is an appealing but presently unproven
hypothesis. In a retrospective cohort study of 3500 adults
without past or current atrial fibrillation who underwent com-
plete overnight polysomnography, both obesity and nocturnal
oxygen desaturation were independent predictors of incident
atrial fibrillation, but only in subjects 65 years of age (66).
Continuous cardiac monitoring with an implanted atrial
defibrillator showed that episodes of persistent atrial
tachyarrhythmias in OSA patients are more likely to occur at
night (241). Postoperative atrial fibrillation also may be more
likely to occur in patients with OSA (242). An estimated 50%
of atrial fibrillation patients presenting for cardioversion are
likely to have OSA compared with an 30% likelihood of
OSA in a general cardiology clinic population (243). The role
of atrial fibrillation in any increased risk of stroke in patients
with OSA remains to be determined (214).
Ventricular Arrhythmias. Ventricular arrhythmias, primarily
premature ventricular contractions, have been reported in up
to 66% of patients with sleep apnea, which is significantly
higher than the rates reported in persons without sleep apnea
(0% to 12%) (226,227). However, there are no conclusive
data demonstrating a primary etiologic role for OSA in
ventricular arrhythmias.
In most OSA patients, ventricular arrhythmias appear most
often during sleep, with the greatest frequency occurring
during apneic periods (244–246). This is a very different
pattern of ventricular arrhythmia distribution compared with
individuals without OSA. Recent data suggest that in heart
failure patients with OSA and in normal sinus rhythm,
ventricular ectopic beats occur more frequently during the
apneic phases than during hyperpnea (247). This is in contrast
to those patients with CSA, in whom ventricular ectopy was
noted to occur more frequently during hyperpneas than
apneas. Although investigators may disagree on whether
OSA patients without coexisting cardiovascular disease are
more susceptible to ventricular arrhythmias compared with
the non-OSA patient population, there is a perception that
ventricular arrhythmias are most likely to occur in persons
with the more severe forms of OSA and comorbid cardiovas-
cular diagnoses (248). In the Sleep Heart Health Study, a
significant relationship was noted between SDB and noctur-
nal ventricular ectopy (P0.0003) when it was considered a
continuous outcome (231).
The mechanisms by which OSA induces ventricular ar-
rhythmias are uncertain. However, hypoxemia, bradyarrhyth-
mias, and sympathetic activation induced by apneic events
may play important roles. In one of the few studies to identify
a specific hypoxemia level and link it to ventricular ectopy,
Shepard et al (246) found an increase in the frequency of
premature ventricular beats when oxygen saturations fell
intermittently below 60%.
Treatment of Sleep Apnea: Effects on Arrhythmias
There are no conclusive epidemiologic or longitudinal inter-
vention studies relating specifically to prevalence, severity,
and consequences of cardiac arrhythmias and effects of OSA
treatment. For bradyarrhythmias certainly, apneic events may
be a primary cause in the absence of other coexisting
pathology. Note, however, that bradyarrhythmias have been
reported in REM sleep even in healthy young subjects (249).
If the underlying cardiac conduction system is normal and
there is no significant thyroid dysfunction, bradyarrhythmias
or heart block, both of which occur during apneic periods,
may be treated effectively with CPAP or, if necessary, with
tracheostomy (230,244,245,250). Observational data suggest
that the presence of untreated OSA in patients after successful
cardioversion for atrial fibrillation is associated with an 82%
risk for recurrence of atrial fibrillation within 1 year, about
double the risk seen in effectively treated OSA patients after
cardioversion (251). Treatment of OSA may decrease the
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incidence and severity of ventricular arrhythmias (244,245).
In a randomized controlled trial of 1-month duration involv-
ing patients with OSA and systolic dysfunction, abolition of
OSA by CPAP resulted in a 58% reduction in the frequency
of ventricular premature complexes during sleep and a
parallel reduction in nocturnal urinary norepinephrine con-
centrations (252).
Treatment of Arrhythmias: Effects on Sleep Apnea
An initial report of atrial overdrive pacing in patients with
pacemaker implantation (253) for bradyarrhythmia demon-
strated a 50% reduction in obstructive apneas (from 6 to 3 per
hour) and generated considerable interest in the concept of
overdrive pacing for the treatment of OSA. However, this
finding has not been replicated in subsequent investigations
involving somewhat different patient populations (254–256).
In a study comparing atrial overdrive pacing with CPAP, at
both 24 hours and 1 month after initiation of treatment in
patients with OSA, atrial overdrive pacing had no significant
effect on OSA severity, whereas CPAP was highly effective
in treating OSA (257). A prospective, single-blinded, ran-
domized crossover trial of overnight temporary atrial pacing
at 75 bpm in patients with moderate to severe OSA also
showed that pacing did not significantly affect the AHI or the
minimum nocturnal oxygen saturation (258). Recent data
confirm that despite a mild effect of atrial overdrive pacing on
respiratory events in some heart failure patients with OSA,
compared with CPAP, atrial overdrive pacing was not ther-
apeutically effective in improving SDB (259). There is
currently no definitive evidence to support atrial overdrive
pacing as a treatment option for OSA.
Myocardial Ischemia and Infarction
Prevalence of Sleep Apnea in Coronary Artery Disease
The prevalence of SDB in coronary artery disease patients
has been shown to be up to 2-fold greater than in non–
coronary artery disease subjects (260–263).
Evidence That OSA Contributes to the Origin and
Progression of Coronary Artery Disease
Severe intermittent hypoxemia, acidosis, increased BP, and
sympathetic vasoconstriction, in conjunction with simulta-
neous changes in intrathoracic and cardiac transmural pres-
sures, all argue compellingly for obstructive apneas as a
potential trigger for cardiac ischemia. In the longer term, the
cardiac and vascular disease mechanisms described earlier,
including endothelial dysfunction and systemic inflammation,
may promote structural coronary artery damage. In a study of
200 consecutive patients without a history of coronary
artery disease who underwent electron-beam computed to-
mography within 3 years of polysomnography, the median
coronary artery calcification score (Agatston units) was 9 in
OSA patients and 0 in non-OSA patients (P0.001) (264).
Median calcification score increased as OSA severity wors-
ened (P for trend by AHI quartile 0.001). Multivariate
analysis confirmed an independent association between OSA
and subclinical coronary artery disease, as measurable by
coronary artery calcification.
Sleep apnea has been implicated in patients with nocturnal
angina pectoris. Nocturnal angina and ST depression are
diminished during treatment of sleep apnea by CPAP
(186,265). Similarly, Hanly et al (266) noted the ST depres-
sion occurred in about a third of patients with severe OSA. ST
depression was markedly attenuated during nasal CPAP.
However, these patients did not have proven coronary artery
disease, and artifactual ST changes related to breathing
patterns may have contributed. In patients with established
coronary artery disease and moderate or severe OSA (AHI
15), there was no evidence of nocturnal myocardial injury
detectable by measurements of cardiac troponin T (267).
In longer-term studies, SDB in patients with coronary
artery disease was associated with a significant increase in the
composite end point of death, myocardial infarction, and
cerebrovascular events at a 5-year median follow-up interval
(268). This composite end point occurred in 28% of men with
SDB and in 16% of men without SDB. The corresponding
percentages for women were 20% and 14%. However, neither
oxygen desaturation index nor AHI was independently pre-
dictive of single end points of myocardial infarction or death
(268). In a case-control study, there was a graded increase in
the odds of acute myocardial infarction with increased sleep
apnea severity, even after adjustment for possible confound-
ing factors (269). A recent study of 500 subjects reported
that people with OSA are more likely than those without OSA
to have a family history of premature death from coronary
artery disease independently of gender, BMI, and personal
history of coronary artery disease (OR, 2.13; 95% CI, 1.04 to
4.66; P0.046) (270).
Although much is known about the association between
sleep apnea and stroke, arrhythmias, coronary artery disease,
and myocardial ischemia and infarction, the data provide
mostly observational, albeit valuable, insights. Although
longitudinal data regarding independent effects of sleep
apnea on stroke, cardiac ischemia, and lethal ventricular
arrhythmias are limited, recent evidence suggests that in
patients experiencing sudden cardiac death, those proven to
be free of OSA have the greatest likelihood of death between
6 and 11 AM, the traditional window of cardiovascular
vulnerability (271). In striking contrast, more than half of
sudden cardiac deaths in patients with proven OSA occur
during the sleeping hours, between 10 PM and 6 AM. Thus,
OSA appears to affect the timing of sudden cardiac death;
however, it is not yet known whether OSA increases the
overall risk of sudden cardiac death.
Treatment of OSA: Effects on Myocardial Ischemia
and Infarction
An observational study suggested that in patients with com-
bined OSA and coronary artery disease, treatment of OSA
was associated with a decrease in the occurrence of new
cardiovascular events (272). A second prospective observa-
tional study assessed the incidence of fatal and nonfatal
cardiovascular events in healthy men, snorers, and patients
with treated and untreated OSA. In men with severe untreated
OSA (AHI 30), both fatal and nonfatal cardiovascular
events were markedly increased. In contrast, fatal and non-
fatal cardiovascular events in treated OSA patients ap-
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proached levels seen in simple snorers (180). In a third
observational study comparing cardiovascular outcomes in
107 CPAP-treated and 61 CPAP-intolerant patients, total
cardiovascular deaths were more common in the untreated
group (P0.0009) (150). Several mechanisms and even
benefits from intervention have been inferred from the
available observational data (273). However, there are no
randomized trials of the effects of treatment of OSA on risk
of developing coronary artery disease, risk of myocardial
infarction, or risk of cardiovascular death.
Treatment of Coronary Artery Disease: Effects on
Sleep Apnea
Although anecdotal reports from patients’ spouses describe
marked changes in sleep patterns, snoring severity, and
witnessed apneas after bypass surgery and sometimes even
after angioplasty, this phenomenon awaits more comprehen-
sive study. Any improvement in left ventricular function from
relief of cardiac ischemia could potentially attenuate airway
obstruction and CSA, as discussed earlier.
Pulmonary Arterial Hypertension
The Prevalence of OSA in Pulmonary
Arterial Hypertension
There are frequent episodes of increased pulmonary artery
pressure during sleep in patients with OSA. It is less certain
whether daytime pulmonary arterial hypertension also occurs
in patients who do not have coexisting pulmonary or heart
disease. Most of the studies that have addressed this question
have used echocardiography to estimate pulmonary artery
pressure, but some have used more precise right heart
catheterization. In 1 series of 220 consecutive patients with
OSA and an AHI 20, pulmonary arterial hypertension
(mean arterial pressure 20 mm Hg) was found in 17% of
patients (274). However, it was relatively mild (only 2 of 37
patients had a pulmonary artery pressure 35 mm Hg).
These patients also tended to be more obese and to have
hypoxemia and hypercapnia while awake, and some may
have had underlying chronic obstructive pulmonary disorder.
Other smaller series of patients with OSA but no clinical
history of chronic obstructive pulmonary disorder have re-
ported daytime pulmonary arterial hypertension in 20% to
42% of cases (275–277).
OSA and the Origin and Progression of Pulmonary
Arterial Hypertension
The most likely primary mechanism for any OSA-related
pulmonary arterial hypertension is hypoxemia, which is
known to reflexively induce an acute increase in pulmonary
arterial pressure (278,279). However, there is debate as to
whether OSA can be a primary cause of sustained pulmonary
arterial hypertension. The most direct evidence comes from
observations that treatment of OSA with CPAP may lower
daytime pulmonary artery pressure (280). The pulmonary
arterial hypertension seen in association with OSA is gener-
ally mild and can be attributed to an elevated pulmonary
vascular resistance because cardiac output and capillary
wedge pressure are normal, at least at rest (274). Pulmonary
hypertensive OSA patients appear to have increased pulmo-
nary vascular reactivity to hypoxia compared with patients
without pulmonary arterial hypertension (281), and CPAP has
been reported to decrease pulmonary vascular reactivity to
hypoxia (280). An unresolved issue is whether nocturnal
hypoxemia can lead to daytime pulmonary arterial hyperten-
sion or whether daytime hypoxemia, which is commonly
observed in these patients, also is required. Two confounding
factors that may contribute to daytime hypoxemia are severe
obesity (obesity-hypoventilation syndrome) and chronic ob-
structive pulmonary disorder in association with OSA (the
so-called overlap syndrome) (281). Thus, despite acute noc-
turnal increases in pulmonary artery pressure associated with
obstructive apneas, proof that OSA causes pulmonary arterial
hypertension has been limited by obesity, technical concerns
regarding noninvasive measurements of pulmonary artery
pressure in obese OSA patients, comorbidities and medica-
tion use in this population, and difficulties in identifying
suitable control subjects (6). Nevertheless, the most recent
clinical classification of pulmonary hypertension identifies
SDB in the category of respiratory disorders associated with
pulmonary hypertension (282).
Treatment of OSA: Effects on Pulmonary
Arterial Hypertension
Sleep studies are probably an appropriate part of the evalua-
tion of the patient with pulmonary arterial hypertension (283).
When elevated in patients with OSA, pulmonary artery
pressures have been reported to fall after treatment with
CPAP (280,284,285). In an early study of 6 patients with
OSA, tracheostomy was associated with marked declines in
pulmonary artery pressure measured during sleep (286).
However, other studies have found less consistent changes,
but in many patients, the pulmonary artery pressure was
normal before CPAP was begun (287). In a recent random-
ized crossover study of 12 weeks of effective versus sham
CPAP in 23 patients with OSA, effective CPAP was associ-
ated with decreases in echocardiographic measurements of
pulmonary artery systolic pressure (288). Two patients who
could not tolerate therapeutic CPAP were excluded from
analysis. Pulmonary artery pressures were especially reduced
in those patients with pulmonary hypertension or left ventric-
ular diastolic dysfunction at baseline. Larger randomized
studies are needed to identify more definitively any sustained
effects of CPAP therapy on pulmonary hypertension and right
heart function and to better establish any role for CPAP as
one of the rapidly evolving therapeutic options for pulmonary
hypertension.
End-Stage Renal Disease
Prevalence of OSA in End-Stage Renal Disease
Excessive daytime sleepiness is reported by most patients
with end-stage renal disease (ESRD). The general area of
sleep disorders in ESRD has been reviewed recently by Perl
and colleagues (289). ESRD patients often exhibit a mixed
SDB pattern with both obstructive and central components
(290–292). When studied by polysomnography in a few
small series of selected subjects, the prevalence of OSA in
ESRD ranged from 40% to 60% (290–292).
699JACC Vol. 52, No. 8, 2008 Somers et al.
August 19, 2008:686–717 AHA/ACC Sleep Apnea and Cardiovascular Disease
OSA and the Origin and Progression of ESRD
The most direct mechanism by which long-standing OSA
might contribute to the origin of ESRD is by inducing chronic
elevations in BP. OSA could further contribute to the pro-
gression of ESRD by acutely increasing sympathetic nerve
discharge directed at the kidney and other vascular beds,
raising BP during episodes of upper airway occlusion, and
chronically accelerating the progression of renal damage
(293,294), with sustained elevations in BP during the awake
state (295,296). OSA has also been linked to glomerular
hyperfiltration (297). Whether OSA is an independent pre-
dictor of proteinuria is controversial (298,299).
Importantly, coexisting OSA may increase the likelihood
of cardiovascular complications, which are the principal
cause of morbidity and mortality in ESRD patients (295,300).
For example, in the ESRD population, systemic hypertension
(301), increased sympathetic activity (302), nocturnal hypox-
emia (303), and left ventricular hypertrophy (304) may
independently increase the risk of subsequent cardiovascular
events. Furthermore, the frequency of arousal from sleep
resulting from periodic limb movements also may be associ-
ated with premature mortality (305).
Treatment of OSA: Effects on ESRD
Whether treatment of OSA affects the progression of renal
disease is not known.
Treatment of ESRD: Effects on OSA
Although ESRD patients have a high prevalence of OSA,
uremia itself may contribute independently to the pathophys-
iology of OSA by destabilizing central ventilatory control and
causing edematous upper airway narrowing (290), and in-
creased pharyngeal resistance to airflow (200,201). Although
there are case reports of resolution of sleep apnea after renal
transplantation (306,307), the prevalence of OSA in ESRD
patients remains similar before and after the introduction of
peritoneal or conventional hemodialysis (308). However, it
would appear that the severity of OSA can be attenuated with
nocturnal (309) or more aggressive dialysis. When 14 ESRD
patients were studied before and after conversion to nocturnal
home hemodialysis, which increases both the dose and
frequency of dialysis by performing this procedure 6 nights
per week for 6 to 8 hours per night, there was a marked
reduction in the average AHI from 2525 to 88. Seven of
these patients were found to have OSA, with an AHI 15
while on conventional dialysis. Institution of nocturnal home
hemodialysis led to significant increases in minimum and
mean O2 saturation during sleep. Nocturnal heart rate also fell
(310). A reduction in the volume of extracellular fluid in the
upper airway was proposed as a mechanism to explain the
alleviation of OSA (309). Recent data support the concept
that nocturnal peritoneal dialysis is superior to chronic
ambulatory peritoneal dialysis in attenuating sleep apnea as a
result of better fluid clearance during sleep (311).
Treatment Options in OSA
Obesity is the single most important cause of OSA. Weight
loss can lead to a decrease in AHI, improved sleep efficiency,
decreased snoring, and improved oxygenation. The most
dramatic results have been reported with surgical weight loss
(312–314). In addition, apnea often is worse in the supine
posture, with some patients having OSA only in that position
(315,316). For patients with “positional apnea,” behavioral
techniques aimed at keeping the patient in the lateral posture
during sleep (an uncomfortable object sewn into the back of
the nightshirt or positional alarms) may offer benefit.
CPAP, applied via a nasal mask, continues to be the
primary therapy for patients with OSA (59,60). The device
consists of a mask connected to a blower that maintains
positive airway pressure at the desired level, acting as a
pneumatic splint for the pharyngeal airway (317,318). The
prescribed CPAP pressure is generally determined in the
sleep laboratory as that pressure required to eliminate all
snoring, apneas, and hypopneas during all sleep stages and in
all body positions. There is evidence supporting improve-
ments in measures of OSA, daytime sleepiness, and neuro-
cognitive function with nasal CPAP (319–324).
Despite the effectiveness of CPAP in treating OSA, adher-
ence to therapy continues to be a major problem (325,326).
This relates primarily to the facial interface (mask) and the
pressure required to prevent airway collapse, with some
patients finding CPAP intolerable. Most evidence suggests
that proper introduction of and education regarding CPAP, in
both the sleep laboratory and the physician’s office, are
important. Proper humidification of the inspired air, careful
selection of the appropriate mask, and the addition of a
pressure ramp all may improve compliance. In addition, the
use of bilevel positive airway pressure (higher pressure on
inspiration than expiration) or a constantly adjusting, autoti-
trating device may improve patient acceptance.
When CPAP proves unacceptable, oral appliances should
be considered. Most such appliances lead to anterior mandib-
ular repositioning, which acts by pulling the lower jaw (and
thus the tongue) forward, thereby enlarging the pharyngeal
airway (327,328). With the adjustable devices, anterior dis-
placement is minimal at first but is increased slowly over
weeks until snoring and OSA are relieved or until side effects
(primarily temporal mandibular joint pain) occur. Most need
to be custom prepared by a dentist with considerable experi-
ence in the use of these devices. A recent analysis by the
American Academy of Sleep Medicine reported oral appli-
ances to be preferred over CPAP by many patients and to be
successful in improving snoring, but only 52% were success-
ful at relieving OSA (AHI 10) (329).
Surgery continues to be a viable approach to apnea therapy
in some patients, with most procedures designed to enlarge
the pharyngeal airway or bypass the obstruction (330).
Tracheostomy was the first surgical procedure used in the
treatment of apnea and, although effective, is rarely per-
formed now because of its social stigma and discomfort (62).
Uvulopalatopharyngoplasty was the first procedure intro-
duced to enlarge the posterior pharyngeal airspace and to
prevent airway collapse during sleep. However, efficacy has
been somewhat limited (331). A modified uvulopalatopha-
ryngoplasty procedure using a CO2 laser in the outpatient
setting, called laser- assisted uvuloplasty, appears also to be
of limited efficacy in the treatment of apnea (332).
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There are currently no widely applicable, effective medical
therapies for OSA, except the treatment of predisposing
factors such as hypothyroidism and acromegaly; treating the
underlying condition can significantly improve the AHI
(333). No therapy for sleep apnea is easily accomplished and
acceptable to all patients. Nevertheless, OSA should be
considered a treatable condition. Therapy must be individu-
alized on the basis of the severity of the disease, patient
preferences, and anatomy of the upper airway.
Central Sleep Apnea
Epidemiology
The cause of CSA, apart from its occurrence as a prevalent
comorbid condition of heart failure, stroke, and late-life aging
(15,334), is not completely understood. The prevalence of
CSA in the general population has been estimated in 2
population cohorts. In a southern Pennsylvania cohort, CSA
at a severity level of 20 apneas per hour (central apnea
index [CAI] 20) was not seen in men 65 years of age or
women of any age (44,45). In men 65 years of age, the
prevalence was 5%. For CAI 2.5, the prevalence estimates
for men in groups 20 to 44, 45 to 64, and 65 to 100 years of
age were 0%, 1.7%, and 12%, respectively. The steep rise in
CSA with older age was accompanied by a decrease in
severity of OSA. In the Sleep Heart Health Study, in which
age ranged from 40 to 97 years, the prevalence of CAI 1
was 9% (335). Regardless of the threshold used, prevalence
was higher in those with diabetes compared with those
without diabetes; eg, for CAI 4, prevalence was 2.5% and
1.6%, respectively (336). The demographics and other corre-
lates of CSA in the general population have not been
characterized.
A high frequency of CSA in heart failure, left ventricular
dysfunction (even in the absence of overt heart failure), and
stroke has been widely noted (11,46,334,337). For reasons
yet to be elucidated, fewer women with heart failure have
CSA (47,49,338,339). CSA defined by a CAI 15 was found
in 40% of a sample of 81 male heart failure patients
unselected for sleep apnea symptoms (48), in 29% of 450
patients referred for polysomnography from a heart failure
clinic (47), and in 21% of 218 patients referred subsequently
from the same clinic in a prospective survey (171). Compared
with heart failure patients with OSA, those with CSA may be
more likely to be male and older and to have a lower BMI
(47,334) and a higher pulmonary capillary wedge pressure
(340). Little is known about risk factors for CSA in persons
without heart failure, and data on the prevalence and charac-
teristics of CSA in other types of cardiovascular disease are
sparse.
Clinical Presentation
There are considerably fewer published reports on patients
with CSA. Patients with heart failure and CSA may complain
of paroxysmal nocturnal dyspnea and frequent nocturnal
arousals and awakenings. CSA may manifest in the typical
crescendo/decrescendo pattern of CSR. However, snoring,
excessive daytime sleepiness, and obesity are less common
than in patients with OSA. Compared with heart failure
patients without CSA/CSR, heart failure patients with CSA/
CSR were more likely to be older (60 years of age) and
male and to have atrial fibrillation, lower arterial PCO2
(38 mm Hg) (47), and heightened sensitivity to CO2 (36),
Oscillatory breathing patterns evident in heart failure patients
during wakefulness (341) and exercise (38,342) also may
predict both the presence of CSA and poorer prognosis (39).
Thus, in patients with heart failure and 1 of these charac-
teristics, a diagnosis of CSA/CSR should be strongly consid-
ered, and a careful sleep history should be obtained. If sleep
apnea is suspected (frequent arousals and awakenings, wit-
nessed apnea, or paroxysmal nocturnal dyspnea), diagnostic
polysomnography should be considered.
Mechanisms of Disease and Associated
Cardiovascular Risk
Patients with asymptomatic left ventricular dysfunction and
CSA have evidence for greater cardiac electric instability
compared with patients with asymptomatic left ventricular
dysfunction without CSA (337). In patients with heart failure,
high levels of resting sympathetic drive increase even further
during episodes of central apnea (343). Urine and plasma
norepinephrine levels and muscle sympathetic nerve traffic
during wakefulness are greater in heart failure patients with
CSA compared with those without CSA (177,344). However,
it has been proposed that heightened sympathetic drive in
heart failure patients with CSA may simply be a consequence
of more severe heart failure rather than a direct consequence
of CSA (345). The role of inflammatory and other mecha-
nisms in CSA remains unclear, in contrast to OSA, in which
hypoxemia is usually more severe. Clarification of these
mechanisms is especially difficult because of the multiple
other comorbidities and medications that may influence these
measurements in heart failure patients.
CSA in Heart Failure
Although OSA has been identified as a possible independent
risk factor for the development of heart and vascular disease,
CSA more often is a consequence of such cardiovascular
illness, although it can occur even in healthy subjects,
especially at altitude. CSA/CSR is characterized by oscilla-
tion of tidal volumes resulting in PaCO2 levels below the
apneic threshold. Increases in the respiratory rate, or hyper-
ventilation, seen in association with heart failure or stroke
produce PaCO2 levels below the threshold, leading to suppres-
sion of central nervous system stimulation to the respiratory
muscles and hence to central apnea. The overall mechanisms
underlying CSA are complex and include chemoreflexes,
pulmonary congestion, increased cardiac filling pressures,
and prolonged circulation time (346–348).
It is not yet known whether CSA is an epiphenomenon in
the setting of heart failure or whether it may itself lead to
increased risk or progression of heart failure (337,339,
349,350). In a study from Lanfranchi and colleagues (339), a
variety of baseline patient characteristics, including New
York Heart Association class, left ventricular ejection frac-
tion, and exercise capacity (determined by metabolic exercise
testing), predicted mortality in a group of heart failure
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patients. Left atrial area and the AHI emerged as the 2 most
potent predictors of mortality. On average, nonsurvivors had
an AHI that was 2-fold higher than survivors. In particular, an
AHI of 30 was associated with very poor outcome, espe-
cially in the setting of left atrial enlargement. Thus, the
structurally abnormal heart may be less able to tolerate
repetitive nocturnal apneas. Other studies also suggest that
the higher rates of death and cardiac transplantation seen in
patients with heart failure are proportional to the frequency of
central apneic events (349) and that, along with CSA, other
variables predicting survival include low diastolic BP and
severe right ventricular dysfunction (351). OSA and CSA
also may coexist in patients with heart failure. In 12 heart
failure patients with primarily OSA at the onset of sleep,
lung-to-ear circulation time rose, PCO2 fell, and OSA con-
verted to CSA over the course of a single night (352). A
similar progression from predominantly OSA to predomi-
nantly CSA has been observed over a 1-month time frame in
conjunction with a decrease in nocturnal PCO2 and an increase
in periodic breathing cycle length (353).
Treatment Options in CSA
Because no randomized trials of therapy for CSA in heart
failure have established a significant benefit with respect to
hospitalization or mortality, there is no consensus as to
whether CSA should be treated and, if so, what the optimal
therapeutic strategy may be. However, it seems clear that
optimizing management of the heart failure can improve
CSA. The introduction of angiotensin-converting enzyme
inhibition can lower the AHI and reduce the nocturnal
desaturation of patients with mild to moderate heart failure
(354). Diuresis with a reduction in cardiac filling pressure
also has been shown to reduce the severity of CSA (340), but
in some patients, the resulting metabolic alkalosis may
promote CSA by narrowing the difference between ambient
PaCO2 and the PaCO2 threshold for apnea (355,356).
-adrenergic blockade, which counters excess sympathetic
activation and may modulate ventilatory responses in heart
failure (18), has been reported to decrease AHI in patients
with CSA (357). However, the increasing use of such
antagonists in heart failure appears not to have altered the
prevalence of CSA in this condition (171). Should CSA
persist despite intensified heart failure therapy, other inter-
ventions may be considered.
Nocturnal supplemental O2 has been shown to abolish
apnea-related hypoxia, to alleviate CSA, to decrease noctur-
nal norepinephrine levels over periods of 1 night to 1 month
(291,358,359), and to increase maximum O2 uptake during a
graded exercise test (360). However, when administered for 1
month, O2 had no impact on cardiac function or quality of life
(359). Long-term effects on cardiovascular end points have
not been evaluated.
In a 5-day trial, theophylline reduced the severity of CSA
but did not cause any improvements in right or left ventricular
ejection fraction, quality of life, or clinical variables (361).
The potential adverse consequences of this positive inotropic
and proarrhythmic agent preclude recommending it at this
time for long-term use in patients with advanced heart failure.
In a recent randomized, placebo-controlled, double-blind
crossover protocol, a single dose of acetazolamide before
sleep reduced CSA and attenuated related daytime symptoms
(362). However, at present, there is no evidence to support the
long-term use of acetazolamide to suppress CSA.
In randomized trials of 1 day’s to 3 months’ duration,
several forms of noninvasive positive airway pressure, in-
cluding CPAP, bilevel, and adaptive pressure support ser-
voventilation, have been shown to alleviate CSA in heart
failure patients (363–365). In patients with CSA, short-term
application of CPAP reduced the frequency of ventricular
ectopic beats (245). In randomized trials, nightly application
of CPAP for 3 months increased left ventricular ejection
fraction, reduced mitral regurgitation and nocturnal urinary
and daytime plasma norepinephrine, and improved quality of
life (363,366). Of 29 patients with heart failure and CSA who
participated in a randomized trial of CPAP, those who
complied with this intervention experienced a significant
reduction in the combined rate of mortality and cardiac
transplantation over a 5-year period, although intention-to-
treat analysis did not show significant benefit of CPAP
treatment (367). Another prospective study used a random-
ized parallel design in treating CSR in heart failure patients,
comparing 1 month of therapeutic and subtherapeutic adap-
tive servoventilation (368). Twenty-six patients completed
the trial. Active treatment attenuated daytime sleepiness
(P0.014), the primary end point. Although significant
decreases in secondary end points of plasma brain natriuretic
peptide (P0.001) and urine metadrenaline (P0.018) were
noted, urine metnoradrenaline did not fall (P0.19).
In a multicenter, randomized trial involving 258 patients
with heart failure and CSA (the Canadian Positive Airway
Pressure Trial for Patients With Congestive Heart Failure and
Central Sleep Apnea [CANPAP]) (338), the application of
CPAP reduced nocturnal desaturation and caused a modest
but significant improvement in ejection fraction. However,
the primary results of CANPAP also raised the possibility of
early harm from CPAP, with early divergence of
transplantation-free survival (the primary end point) favoring
the control group (P0.02). After a mean follow-up period of
2 years, the primary outcome of combined mortality and
cardiac transplantation was identical in the treated and control
groups. Hospitalization rates also were unaffected by CPAP.
Unfortunately, despite only a 15% dropout rate in both arms,
this trial was severely underpowered owing to a marked
decline in the annual event rate as advances in medical and
device therapy of heart failure were incorporated into stan-
dard clinical practice. The concerns listed above contributed
to early termination of CANPAP, and the role of CPAP in
heart failure patients with CSA must now be questioned.
The potential implications of the CANPAP findings are
addressed in a recent and informative debate (369,370).
Issues of compliance and efficacy may be relevant. At 1 year,
CPAP was used for 3.6 hours per night and attenuated AHI by
50%, indicating only a partial reduction in “apnea burden.”
Better-tolerated and more effective treatment of CSA might
have resulted in improved survival (214,371,372). In any
event, at this time, CPAP should not be routinely considered
as standard therapy for CSA in heart failure patients. Further-
more, the results of the CANPAP study should not be
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extrapolated to heart failure patients with OSA, which is
much more effectively suppressed by CPAP (194,214).
The limited effects of atrial overdrive pacing on CSA,
including in patients with heart failure, have been discussed
earlier. Some data suggest a role for cardiac resynchroniza-
tion therapy (CRT). In a small, nonrandomized trial of
patients with a mean left ventricular ejection fraction of 24%,
left bundle-branch block, and CSA, CRT lowered the AHI
from 19.2 to 4.6 (373), reduced the desaturation index, and
shortened the apnea-hyperpnea cycle length, a surrogate for
improved cardiac output, by 25%. In another report of
patients already on CRT, discontinuation of pacing resulted in
increased CSA severity within 1 day, with attenuation of CSA
on the following night when CRT was resumed (374).
Changes in CSA appeared to be associated with CRT-induced
changes in mitral regurgitation. Further studies are required to
confirm these early results, to determine the mechanism(s) by
which CRT might improve CSA, and to identify which CSA
patients with heart failure would benefit from such
interventions.
In summary, although CSA has been associated with
increased mortality in heart failure patients, a causal role for
CSA in the morbidity and mortality of heart failure awaits
more definitive evidence. A number of treatment strategies
for CSA have been tested, but presently none is ideal with
respect to both efficacy and tolerance, nor has any available
therapy been demonstrated to improve survival.
OSA in Children
Childhood SDB encompasses children with OSA syndrome,
the syndromes of central hypoventilation, and disorders of
respiratory muscles. Children with comorbid conditions such
as those with genetic syndromes that may alter airway
anatomy, central control of breathing, or respiratory muscle
function represent a large percentage of children presenting to
pediatric sleep centers with SDB. Most published reports on
the cardiovascular morbidity of childhood SDB have in-
cluded children with various forms of SDB and comorbid
conditions. This descriptive literature helped establish a link
between SDB and cardiovascular disease in children but has
limited the ability to estimate in the general population the
cardiovascular risk from each form of SDB.
OSA in children frequently is due to adenotonsillar hypertro-
phy with airway narrowing, with only a modest role for obesity.
Adenotonsillectomy often is an effective treatment. In a recent
longitudinal study of serial polysomnography in children after
adenotonsillectomy (at 6 weeks, 6 months, and 1 year postop-
eratively), BMI, rapidity of increase in BMI, and black race each
conferred increased risk of recurrence of SDB (375). The
epidemic of childhood obesity may be changing the epidemiol-
ogy of OSA in children (376). There is no clear consensus in the
pediatric community regarding which patients deserve an eval-
uation in the sleep laboratory, and decisions are made on a
patient-individualized basis. Therefore, the schematic outlined in
Table 1 is not necessarily applicable to children. Here, we focus
primarily on the available evidence linking OSA to cardiovas-
cular disease in children.
Hypertension
The effect of simple snoring on BP was examined in a study
that included children with snoring but without OSA. Com-
pared with age-, gender-, and BMI-matched control subjects,
children with simple snoring had higher daytime resting
systolic and diastolic BPs (377). Among 14 children with
upper airway obstruction and heart failure, 3 children had severe
hypertension, which improved after treatment of OSA (378).
Nighttime BPs may be higher in children with OSA. BP
recorded during polysomnography in 41 children with OSA
syndrome and 26 children with primary snoring showed a
significantly higher diastolic BP for sleep and wakefulness in
the OSA group. Possibly because of the sample size, no
difference in prevalence of hypertension between the 2
groups was found (379). A study of 23 Japanese children
showed that those with AHI 10 had higher systolic and
diastolic BP indexes during REM sleep and during wakeful-
ness compared with those with AHI10. However, the effect
of BMI on BP was not accounted for in this comparison (380).
In a report on 239 children (51% Hispanic) from the
Tucson Children’s Assessment of Sleep Apnea study, 6% had
hypertension (381). Systolic and diastolic hypertension and
sleep efficiency were independently associated with respira-
tory disturbance index. However, adjusted ORs for confound-
ing variables were not reported. Ambulatory 24-hour BP
recordings on 39 children with OSA and 21 with simple
snoring showed increased BP variability during wakefulness
and sleep and less nocturnal BP dipping in children with OSA
compared with children with simple snoring (382). In addi-
tion to BMI, the frequency of oxygen desaturation during
sleep and AHI were significant predictors for daytime and
nocturnal BP variability, respectively. However, compared
with snoring children, those with OSA did not have higher
daytime or nighttime BP. Finally, 24-hour ambulatory BP
recordings of 96 snoring children demonstrated an indepen-
dent association between sleep diastolic BP and frequency of
nocturnal oxygen desaturation (383).
A common observation among the cross-sectional studies
published in the last 10 years is that BP elevation seen in
association with childhood OSA syndrome rarely surpasses
the 95th percentile. On the basis of the current literature, there
is no definitive evidence that established hypertension is a
common cardiovascular complication of OSA syndrome in
children and adolescents. However, severe hypertension has
been described in advanced stages of OSA in anecdotal
reports (378,380–382,384). Furthermore, a recent study ex-
amined ambulatory BPs in 140 children 7 to 13 years of age
with nightly snoring and tonsillar hypertrophy. In these
otherwise healthy children, an AHI 5 was associated with
an increase in morning BP surge, heightened BP load (per-
centage of BP measurements exceeding the 95th percentile),
and higher 24-hour BP (385).
It is unlikely that mild OSA in children will lead to
significant cardiac dysfunction in the pediatric age range.
However, it is not known whether mild OSA during early
childhood predisposes to vascular injury and/or BP dysregu-
lation during adolescence and adulthood (386). Whether OSA
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is an independent risk factor for systemic hypertension in
children remains unanswered.
Endothelial Dysfunction
In a study of 30 children (mean age, 9.52.8 years) with
primary snoring, pulsed-wave velocity over the forearm was
higher compared with control children (9.71.6 versus
7.92.0 m/s; P0.001). Systolic and diastolic BPs also were
found to be higher in the snoring children (11210 versus
1058 mm Hg, P0.001, and 607 versus 539 mm Hg,
P0.004, respectively). Multiple regression analysis identi-
fied primary snoring as the only significant factor for in-
creased pulsed-wave velocity (377).
Mechanisms of endothelial dysfunction in children have
not yet been investigated. However, pediatric studies have
described upregulation of inflammatory mediators known to
play an important role in vascular injury. P-selectin,
C-reactive protein, fibrinogen, interleukin-8, and interferon-
levels were found to be higher in children with snoring and/or
OSA compared with control subjects (387–391). In a study of
143 adolescents, mean C-reactive protein level demonstrated
a dose-response increase with SDB that was independent of
BMI and partially explained by the severity of nocturnal
hypoxemia (91). Whether these mediators predict cardiovas-
cular risk in children and adolescents has yet to be
demonstrated.
Left Ventricular Structure and Function
Evidence Linking OSA to Left Ventricular Changes
Left ventricular hypertrophy has been described in small case
series (384,392). A case-control study showed that left
ventricular mass and relative wall thickness were significantly
greater in normotensive children with polysomnography-proven
OSA compared with children with primary snoring and that
an AHI 10 increased 6-fold the risk for left ventricular
hypertrophy (393).
In 29 adolescents with SDB, compared with 11 control
subjects, left ventricular posterior wall thickness correlated
with respiratory disturbance index, but no difference in left
ventricular mass was found between the 2 groups (394).
Another study further demonstrated a dose-dependent de-
crease in left ventricular diastolic function with increased
severity of OSA (395). In children with snoring, the overnight
increase in brain natriuretic peptide, a hormone released by
ventricular myocytes in response to pressure and volume
overload, was found to correlate with severity of the disorder
(396). The severity of sleep apnea may thus determine the
presence of cardiac functional and structural changes. In
otherwise healthy children, those with more severe SDB
(AHI 5) had higher activity-adjusted ambulatory BP and
echocardiographic evidence of increased left ventricular wall
thickness (385).
Effects of Treatment of OSA on the Left Ventricle
Left ventricular end-diastolic dimension and thickness of
interventricular septum were found to be significantly greater
in children with adenotonsillar hypertrophy who were clini-
cally diagnosed with OSA on the basis of history and level of
oxygen saturation during sleep compared with control sub-
jects (397). Adenotonsillectomy was associated with a reduc-
tion in left ventricular dimension and posterior wall and
septal thicknesses. However, no statistical analysis was re-
ported for these data. Two other studies have described a
trend toward an improvement of left ventricular ejection
fraction after surgical treatment of OSA (398,399).
The mechanism of left ventricular hypertrophy in children
with OSA is not well understood. Similarly, the degree of
reversibility of abnormal left ventricular geometry after
treatment has not been comprehensively examined. Existing
data are largely confounded by a lack of comprehensive
evaluation of the presence and severity of OSA in children.
Pulmonary Hypertension
Evidence Linking OSA to Pulmonary Hypertension
Literature on the relationship between OSA and pulmonary
hypertension in children consists of single case reports
(400–405) and small case series (406–411). To date, no
controlled studies have examined the prevalence of pulmo-
nary hypertension across the spectrum of severity of OSA.
Case series of clinic-based populations of children with OSA
described ECG and echocardiographic findings consistent
with cor pulmonale. Polysomnography was used in 43% of
the reports, whereas the remaining studies relied on the
presence of tonsillar hypertrophy and history of snoring to
make a diagnosis of OSA.
In a case series of 22 children with polysomnography-
proven OSA, 55% had cor pulmonale diagnosed by ECG and
chest radiography. Genetic syndromes were present in 27% of
the cases, and 2 children had coexistent congenital heart
disease (406). In another case series, 16 children who
presented with unexplained cor pulmonale were diagnosed
with different forms of SDB. OSA was present in 68% and
genetic syndromes were present in 45% of the children with
OSA (392).
The effect of OSA on the pulmonary circulation in children
without comorbid conditions was examined in 4 studies (408–
411). Two of these studies, with a total of 64 children, found no
evidence of pulmonary hypertension (409,410), whereas another
study found that all 17 children with adenotonsillar hypertrophy
and symptoms of OSA had pulmonary hypertension (411). The
fourth study gave a clinical description of selected children with
adenotonsillar hypertrophy and cor pulmonale (408).
Direct measurements of pulmonary artery pressure by
cardiac catheterization are limited to 2 case reports (412,413).
Pulmonary hypertension was diagnosed by cardiac catheter-
ization in 3 children with symptoms of OSA, adenotonsillar
hypertrophy, and cardiac failure. Complete reversibility of
pulmonary hypertension was shown in 1 case after adenoton-
sillectomy (412). A second report on 2 children with Down’s
syndrome and 1 child with Pierre Robin sequence showed
evidence of pulmonary hypertension that partially decreased
with oxygen supplementation (413).
Effects of Treatment of OSA on Pulmonary
Hypertension
Ten publications (of which 6 were case reports) (400–404)
noted an improvement of pulmonary hypertension after treat-
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ment of OSA. In a study by Hunt and Brouillette (392),
treatment of 10 children with OSA was associated with complete
resolution of cor pulmonale in 9 cases and partial improvement
in 1 case. In a series by Brouillette et al (406), 12 children with
cor pulmonale improved after treatment. Levine and Simpser
(414) described 4 children with trisomy 21 who improved after
treatment of OSA. In these studies, the cardiovascular outcome
after treatment of OSA was determined on the basis of improve-
ment versus no improvement in clinical symptoms, right ven-
tricular hypertrophy, and/or cardiomegaly and thus was descrip-
tive in nature. A single study demonstrated in 17 children a
decrease in pulmonary artery pressure measured by echocardi-
ography after treatment of OSA (411).
Summary
The current literature regarding pediatric SDB has a number
of limitations. Many studies rely on clinical history alone,
which does not discriminate between primary snoring and
OSA. This precludes an accurate estimation of cardiovascular
morbidity in children with OSA (415). Most reports lack a
uniform definition of pulmonary hypertension and used
diverse methods of testing for the presence of cor pulmonale.
Most studies that found a high prevalence of pulmonary
hypertension described children with polysomnography-
proven severe OSA or children with clinical signs of cardiac
dysfunction. Thus, most cohorts are not representative of the
general population. The inclusion in many of the reports of
children with comorbid conditions such as those with genetic
syndromes, developmental delay, encephalopathy, and coma
leaves the literature with a relatively small number of
children with uncomplicated OSA. These limitations contrib-
ute to the large discrepancy in the reported prevalence of
pulmonary hypertension in children with OSA.
Hence, the prevalence of cor pulmonale in children with
uncomplicated OSA cannot be estimated. The levels of
severity of OSA and/or intermittent hypoxia associated with
any increased risk for cor pulmonale are not known. Whether
the risk for pulmonary vascular disease or other adverse
cardiovascular changes differs in various pediatric age groups
also is unknown. Furthermore, the pathophysiology of cor
pulmonale and the contribution of pulmonary venous hyper-
tension to overall pulmonary artery pressure in children with
OSA are not well understood.
Future Directions: A National Center
on Sleep Disorders Research/
National Heart, Lung, and Blood
Institute Perspective
The National Center on Sleep Disorders Research (NCSDR)
was established by Congress in 1993. Because of the emerg-
ing evidence of associations between untreated SDB and
cardiovascular disease, the NCSDR was established as a
center within the National Heart, Lung, and Blood Institute
(NHLBI). National Institutes of Health (NIH) funding of new
initiatives related to SDB and cardiovascular disease has
progressively increased, stimulated in large part by release of
the first National Sleep Disorders Research Plan in 1996. The
updated and expanded National Sleep Disorders Research
Plan includes prioritized recommendations for future research
to address existing gaps in our knowledge regarding SDB and
cardiovascular disease. These include the following:
● The interaction between cardiac dysfunction and the ven-
tilatory control system in the pathogenesis of CSR.
● Adequately powered clinical trials, particularly in high-risk
populations, to assess the impact of therapy of SDB on
hypertension, cardiovascular disease, metabolic syndrome,
cardiac dysfunction, quality of life, and survival.
● Longitudinal normative data on sleep and cardiorespiratory
patterning in children.
● Genes and gene products that may contribute to the
cardiovascular pathophysiology of SDB. Conducting these
studies in pediatric populations may have distinct advan-
tages because they are less likely to be “contaminated” by
age-associated comorbidities present in adult populations.
● Longitudinal studies to assess the long-term impact of SDB
during childhood and into adulthood, especially consider-
ing the increasing prevalence of obesity in children.
● New and improved modalities for the treatment of SDB,
including pharmacological, surgical, oral appliance, behav-
ioral, muscle stimulation, and alternate strategies to im-
prove efficacy of and compliance with CPAP.
● Novel noninvasive screening/diagnostic methodologies
that are less expensive and more widely applicable than
standard full polysomnography.
The NCSDR, NHLBI, and Trans-NIH Sleep Research
Coordinating Committee encourage clinical investigators to
actively address existing gaps in knowledge regarding SDB
and cardiovascular disease. In addition to the National Sleep
Disorders Research Plan, potential investigators should con-
sult the 2 recent NIH program announcements, Research on
Sleep and Sleep Disorders (R01) (http://grants.nih.gov/
grants/guide/pa-files/PA-07-140.html) and Research on Sleep
and Sleep Disorders (R21) (http://grants.nih.gov/grants/
guide/pa-files/PA-06-238.html).
Summary
In the context of the current epidemics of obesity, hypertension,
atrial fibrillation, and heart failure, the prevalence and conse-
quences of both OSA and CSA are likely to increase. Numerous
hurdles face the cardiovascular community in the development
of consensus regarding best practice. One objective of this
document is to help develop the platform from which, in
collaboration with specialists in sleep medicine and related
disciplines, such consensus may emerge. Challenges to be met
include 1) the general absence of any structured sleep medicine
education in cardiovascular training programs; 2) the logistic and
economic obstacles to diagnosing and treating sleep apnea; 3)
widespread comorbidities, including obesity, that obscure
clearer understanding of any independent cardiovascular conse-
quence of sleep apnea per se; 4) treatment options that are
varied, predominantly device based, and not easily tolerated,
particularly in patients with CSA; and 5) the absence of robust
longitudinal interventional studies addressing whether treating
sleep apnea confers any tangible benefit in terms of cardiovas-
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cular events. We also remain uncertain about what in the apneic
patient facilitates cardiovascular disease and its progression.
There is no clear evidence as to the best measurement for
quantifying the severity of sleep apnea. Is it the frequency of
apneas, the severity of desaturation, the overall burden of
nocturnal hypoxemia, the arousals, sleep deprivation, or a
combination of these and perhaps other characteristics that are
key in promoting heart and blood vessel damage? In addition,
we do not know the threshold of severity of apnea that we should
treat and whether the thresholds for therapy are different in
people with cardiovascular disease compared with those who are
otherwise healthy.
Recognition that a multidisciplinary strategy is critical to
appropriate evaluation of sleep-related disease (416) and
heightened interaction between specialists in cardiovascular
and sleep medicine hold promise for future improved and
integrated patient care. In the meantime, the relative lack of
definitive outcomes data to guide clinical practice necessi-
tates a highly individualized approach to evaluation and
management of those patients with comorbid cardiovascular
disease and sleep apnea.
There will likely be continued rapid evolution in interpre-
tation, dissemination, and implementation of mechanistic,
prognostic, and therapeutic data. Evidence of activation of
cardiovascular disease mechanisms by sleep apnea and evi-
dence of sleep apnea as an independent etiologic factor in
cardiovascular disease should serve as catalysts for definitive
intervention studies. Important next steps in understanding
and treating SDB as a means of preventing and mitigating
cardiac and vascular disease should include further charac-
terizing fundamental disease mechanisms, identifying eco-
nomical and better-tolerated therapeutic options, confirming
whether therapy attenuates cardiovascular morbidity and
mortality, and defining appropriate therapeutic targets and
cost-effective benefits of such therapy.
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